<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GEMCITABINE HYDROCHLORIDE- gemcitabine hydrochloride injection, powder, lyophilized, for solution </strong><br>Watson Laboratories, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use </span><span class="Bold">gemcitabine for injection, USP</span><span class="Bold"> safely and effectively. See full prescribing information for </span><span class="Bold">gemcitabine for injection, USP</span><span class="Bold">.</span><br><span class="Bold">Gemcitabine for Injection, USP, Powder, Lyophilized, For Solution For Intravenous Use</span><span class="Bold"> </span><br><span class="Bold">Initial U.S. Approval: 1996</span><br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Gemcitabine for injection is a nucleoside metabolic inhibitor indicated for: </p>
<ul class="Disc">
<li>Ovarian cancer in combination with carboplatin (<a href="#_1_1_Ovarian_Cancer">1.1</a>)<br>
</li>
<li>Breast cancer in combination with paclitaxel (<a href="#_1_2_Breast_Cancer">1.2</a>)<br>
</li>
<li>Non-small cell lung cancer in combination with cisplatin (<a href="#_1_3_Non_Small_Cell">1.3</a>)<br>
</li>
<li>Pancreatic cancer as a single-agent (<a href="#_1_4_Pancreatic_Cancer">1.4</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Gemcitabine for injection is for intravenous use only. </p>
<ul class="Disc">
<li>Ovarian cancer: 1000 mg/m<span class="Sup">2</span> over 30 minutes on Days 1 and 8 of each 21-day cycle (<a href="#_2_1_Ovarian_Cancer">2.1</a>)<br>
</li>
<li>Breast cancer: 1250 mg/m<span class="Sup">2</span> over 30 minutes on Days 1 and 8 of each 21-day cycle (<a href="#_2_2_Breast_Cancer">2.2</a>)<br>
</li>
<li>Non-small cell lung cancer: 4-week schedule, 1000 mg/m<span class="Sup">2</span> over 30 minutes on Days 1, 8, and 15 of each 28-day cycle: 3-week schedule; 1250 mg/m<span class="Sup">2</span> over 30 minutes on Days 1 and 8 of each 21-day cycle (<a href="#_2_3_Non_Small_Cell">2.3</a>)<br>
</li>
<li>Pancreatic cancer: 1000 mg/m<span class="Sup">2</span> over 30 minutes once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles should consist of infusions once weekly for 3 consecutive weeks out of every 4 weeks (<a href="#_2_4_Pancreatic_Cancer">2.4</a>)<br>
</li>
<li>Dose reductions or discontinuation may be needed based on toxicities (<a href="#_2_1_Ovarian_Cancer">2.1</a> to <a href="#_2_4_Pancreatic_Cancer">2.4</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>200 mg vial for injection (<a href="#_3_DOSAGE_FORMS">3</a>)<br>
</li>
<li>1 g vial for injection (<a href="#_3_DOSAGE_FORMS">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to gemcitabine (<a href="#_4_CONTRAINDICATIONS">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Infusion time and dose frequency: Increased toxicity with infusion time &gt;60 minutes or dosing more frequently than once weekly. (<a href="#_5_1_Infusion_Time">5.1</a>)<br>
</li>
<li>Hematology: Monitor for <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, which can be dose-limiting. (<a href="#_5_2_Hematology">5.2</a>, <a href="#_5_7_Laboratory_Tests">5.7</a>)<br>
</li>
<li>Pulmonary toxicity: Discontinue gemcitabine for injection immediately for severe pulmonary toxicity. (<a href="#_5_3_Pulmonary">5.3</a>)<br>
</li>
<li>Renal: Monitor renal function prior to initiation of therapy and periodically thereafter. Use with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Cases of <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span> (HUS) and/or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, some fatal, have occurred. Discontinue gemcitabine for injection for HUS or severe renal toxicity. (<a href="#_5_4_Renal">5.4</a>)<br>
</li>
<li>Hepatic: Monitor hepatic function prior to initiation of therapy and periodically thereafter. Use with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Serious hepatotoxicity, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have occurred. Discontinue gemcitabine for injection for severe hepatic toxicity. (<a href="#_5_5_Hepatic">5.5</a>)<br>
</li>
<li>Pregnancy: Can cause fetal harm. Advise women of potential risk to the fetus. (<a href="#_5_6_Pregnancy">5.6</a>, <a href="#_8_1_Pregnancy">8.1</a>)<br>
</li>
<li>Radiation toxicity. May cause severe and life-threatening toxicity. (<a href="#_5_8_Radiation_Therapy">5.8</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions for the single-agent (≥20%) are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, ALT, AST, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (<a href="#_6_1_Clinical_Trials">6.1</a>) </p>
<p class="Highlighta"><span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Watson Laboratories, Inc. at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1</span><span class="Bold">
		     
	INDICATIONS AND USAGE</span></a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold">1.1</span><span class="Bold">
		     
	Ovarian Cancer</span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="Bold">1.2</span><span class="Bold">
		     
	Breast Cancer</span></a></h2>
<h2><a href="#section-1.3" class="toc"><span class="Bold">1.3</span><span class="Bold">
		     
	Non-Small Cell Lung Cancer</span></a></h2>
<h2><a href="#section-1.4" class="toc"><span class="Bold">1.4</span><span class="Bold">
		     
	Pancreatic Cancer</span></a></h2>
<h1><a href="#section-2" class="toc"><span class="Bold">2</span><span class="Bold">
		     
	DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1</span><span class="Bold">
		     
	Ovarian Cancer</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2</span><span class="Bold">
		     
	Breast Cancer</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3</span>
		     
	<span class="Bold">Non-Small Cell Lung Cancer</span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.4</span>
		     
	<span class="Bold">Pancreatic Cancer</span></a></h2>
<h2><a href="#section-2.5" class="toc"><span class="Bold">2.5</span>
		     
	<span class="Bold">Preparation and Administration Precautions</span></a></h2>
<h2><a href="#section-2.6" class="toc"><span class="Bold">2.6</span>
		     
	<span class="Bold">Preparation for Intravenous Infusion Administration</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3</span>
		     
	<span class="Bold">DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4</span>
		     
	<span class="Bold">CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5</span>
		     
	<span class="Bold">WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1</span>
		     
	<span class="Bold">Infusion Time</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2</span>
		     
	<span class="Bold">Hematology</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3</span>
		     
	<span class="Bold">Pulmonary</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4</span>
		     
	<span class="Bold">Renal</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5</span>
		     
	<span class="Bold">Hepatic</span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6</span>
		     
	<span class="Bold">Pregnancy</span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7</span>
		     
	<span class="Bold">Laboratory Tests</span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.8</span>
		     
	<span class="Bold">Radiation Therapy</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6</span>
		     
	<span class="Bold">ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1</span>
		     
	<span class="Bold">Clinical Trials Experience</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2</span><span class="Bold">
		     
	Post-Marketing Experience</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7</span><span class="Bold">
		     
	DRUG INTERACTIONS</span></a></h1>
<h1><a href="#section-8" class="toc"><span class="Bold">8</span><span class="Bold">
		     
	USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1</span><span class="Bold">
		     
	Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.3</span><span class="Bold">
		     
	Nursing Mothers</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.4</span><span class="Bold">
		     
	Pediatric Use</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.5</span><span class="Bold">
		     
	Geriatric Use</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.6</span><span class="Bold">
		     
	Renal</span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="Bold">8.7</span><span class="Bold">
		     
	Hepatic</span></a></h2>
<h2><a href="#section-8.7" class="toc"><span class="Bold">8.8</span><span class="Bold">
		     
	Gender</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10</span><span class="Bold">
		     
	OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11</span><span class="Bold">
		     
	DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12</span><span class="Bold">
		     
	CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1</span><span class="Bold">
		     
	Mechanism of Action</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.2</span><span class="Bold">
		     
	Pharmacodynamics</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3</span><span class="Bold">
		     
	Pharmacokinetics</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13</span><span class="Bold">
		     
	NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1</span><span class="Bold">
		     
	Carcinogenesis, Mutagenesis, Impairment of Fertility</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14</span><span class="Bold">
		     
	CLINICAL STUDIES</span></a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">14.1</span><span class="Bold">
		     
	Ovarian Cancer</span></a></h2>
<h2><a href="#section-13.2" class="toc"><span class="Bold">14.2</span><span class="Bold">
		     
	Breast Cancer</span></a></h2>
<h2><a href="#section-13.3" class="toc"><span class="Bold">14.3</span><span class="Bold">
		     
	Non-Small Cell Lung Cancer (NSCLC)</span></a></h2>
<h2><a href="#section-13.4" class="toc"><span class="Bold">14.4</span><span class="Bold">
		     
	Pancreatic Cancer</span></a></h2>
<h2><a href="#section-13.5" class="toc"><span class="Bold">14.5</span><span class="Bold">
		     
	Other Clinical Studies</span></a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">15</span><span class="Bold">
		     
	REFERENCES</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">16</span><span class="Bold">
		     
	HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h2><a href="#section-15.1" class="toc"><span class="Bold">16.1</span><span class="Bold">
		     
	How Supplied</span></a></h2>
<h2><a href="#section-15.2" class="toc"><span class="Bold">16.2</span><span class="Bold">
		     
	Storage and Handling</span></a></h2>
<h1><a href="#section-16" class="toc"><span class="Bold">17</span><span class="Bold">
		     
	PATIENT COUNSELING INFORMATION</span><span class="Bold"> </span></a></h1>
<h2><a href="#section-16.1" class="toc"><span class="Bold">17.1</span><span class="Bold">
		     
	Low Blood Cell Counts</span></a></h2>
<h2><a href="#section-16.2" class="toc"><span class="Bold">17.2</span><span class="Bold">
		     
	Pregnancy</span></a></h2>
<h2><a href="#section-16.3" class="toc"><span class="Bold">17.3</span><span class="Bold">
		     
	Nursing Mothers</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>
<span class="Bold">1</span><span class="Bold">
		     
	INDICATIONS AND USAGE</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_1_1_Ovarian_Cancer"></a><a name="section-1.1"></a><p></p>
<h2>
<span class="Bold">1.1</span><span class="Bold">
		     
	Ovarian Cancer</span>
</h2>
<p class="First">
		     
	Gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_1_2_Breast_Cancer"></a><a name="section-1.2"></a><p></p>
<h2>
<span class="Bold">1.2</span><span class="Bold">
		     
	Breast Cancer</span>
</h2>
<p class="First">
		     
	Gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_1_3_Non_Small_Cell"></a><a name="section-1.3"></a><p></p>
<h2>
<span class="Bold">1.3</span><span class="Bold">
		     
	Non-Small Cell Lung Cancer</span>
</h2>
<p class="First">
		     
	Gemcitabine for injection is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_1_4_Pancreatic_Cancer"></a><a name="section-1.4"></a><p></p>
<h2>
<span class="Bold">1.4</span><span class="Bold">
		     
	Pancreatic Cancer</span>
</h2>
<p class="First">
		     
	Gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for injection is indicated for patients previously treated with 5-FU.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_2_DOSAGE_AND"></a><a name="section-2"></a><p></p>
<h1>
<span class="Bold">2</span><span class="Bold">
		     
	DOSAGE AND ADMINISTRATION</span>
</h1>
<p class="First">
		     
	Gemcitabine for injection is for intravenous use only. Gemcitabine for injection may be administered on an outpatient basis.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="_2_1_Ovarian_Cancer"></a><a name="section-2.1"></a><p></p>
<h2>
<span class="Bold">2.1</span><span class="Bold">
		     
	Ovarian Cancer</span>
</h2>
<p class="First">
		     
	Gemcitabine for injection should be administered intravenously at a dose of 1000 mg/m<span class="Sup">2</span> over 30 minutes on Days 1 and 8 of each 21-day cycle. Carboplatin AUC 4 should be administered intravenously on Day 1 after gemcitabine for injection administration. Patients should be monitored prior to each dose with a complete blood count, including differential counts. Patients should have an absolute granulocyte count ≥1500 x 10<span class="Sup">6</span>/L and a platelet count ≥100,000 x 10<span class="Sup">6</span>/L prior to each cycle.</p>
<p><span class="Underline">Dose Modifications </span></p>
<p>
		     
	Gemcitabine for injection dosage adjustment for hematological toxicity within a cycle of treatment is based on the granulocyte and platelet counts taken on Day 8 of therapy. If marrow suppression is detected, gemcitabine for injection dosage should be modified according to guidelines in Table 1.</p>
<table>
<caption><span>Table 1: Day 8 Dosage Reduction Guidelines for Gemcitabine for Injection in Combination with Carboplatin</span></caption>
<col width="208">
<col width="145">
<col width="190">
<col width="181">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center">Absolute granulocyte count</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center">Platelet count</td>
<td class="Toprule" align="center">% of full dose</td>
</tr>
<tr>
<td align="center">(x 10<span class="Sup">6</span>/L)</td>
<td align="center"></td>
<td align="center">(x 10<span class="Sup">6</span>/L)</td>
<td align="center"></td>
</tr>
<tr>
<td class="Toprule" align="center">≥1500</td>
<td class="Toprule" align="center">And</td>
<td class="Toprule" align="center">≥100,000</td>
<td class="Toprule" align="center">100</td>
</tr>
<tr>
<td align="center">1000 to 1499</td>
<td align="center">and/or</td>
<td align="center">75,000 to 99,999</td>
<td align="center">50</td>
</tr>
<tr class="Last">
<td align="center">&lt;1000</td>
<td align="center">and/or</td>
<td align="center">&lt;75,000</td>
<td align="center">Hold</td>
</tr>
</tbody>
</table>
<p>
		     
	In general, for severe (Grade 3 or 4) non-hematological toxicity, except <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, therapy with gemcitabine for injection should be held or decreased by 50% depending on the judgment of the treating physician. For carboplatin dosage adjustment, see manufacturer’s prescribing information.</p>
<p>
		     
	Dose adjustment for gemcitabine for injection in combination with carboplatin for subsequent cycles is based upon observed toxicity. The dose of gemcitabine for injection in subsequent cycles should be reduced to 800 mg/m<span class="Sup">2</span> on Days 1 and 8 in case of any of the following hematologic toxicities:</p>
<ul class="Disc">
<li>Absolute granulocyte count &lt;500 x 10<span class="Sup">6</span>/L for more than 5 days<br>
</li>
<li>Absolute granulocyte count &lt;100 x 10<span class="Sup">6</span>/L for more than 3 days<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span><br>
</li>
<li>Platelets &lt;25,000 x 10<span class="Sup">6</span>/L<br>
</li>
<li>Cycle delay of more than one week due to toxicity</li>
</ul>
<p>
		     
	If any of the above toxicities recur after the initial dose reduction, for the subsequent cycle, gemcitabine for injection should be given on Day 1 only at 800 mg/m<span class="Sup">2</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_2_2_Breast_Cancer"></a><a name="section-2.2"></a><p></p>
<h2>
<span class="Bold">2.2</span><span class="Bold">
		     
	Breast Cancer</span>
</h2>
<p class="First">
		     
	Gemcitabine for injection should be administered intravenously at a dose of 1250 mg/m<span class="Sup">2</span> over 30 minutes on Days 1 and 8 of each 21-day cycle. Paclitaxel should be administered at 175 mg/m<span class="Sup">2</span> on Day 1 as a 3-hour intravenous infusion before gemcitabine for injection administration. Patients should be monitored prior to each dose with a complete blood count, including differential counts. Patients should have an absolute granulocyte count ≥1500 x 10<span class="Sup">6</span>/L and a platelet count ≥100,000 x 10<span class="Sup">6</span>/L prior to each cycle.</p>
<p><span class="Underline">Dose Modifications </span></p>
<p>
		     
	Gemcitabine for injection dosage adjustment for hematological toxicity is based on the granulocyte and platelet counts taken on Day 8 of therapy. If marrow suppression is detected, gemcitabine for injection dosage should be modified according to the guidelines in Table 2.</p>
<table>
<caption><span>Table 2: Day 8 Dosage Reduction Guidelines for Gemcitabine for Injection in Combination with Paclitaxel </span></caption>
<col width="191">
<col width="158">
<col width="206">
<col width="168">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center">Absolute granulocyte count</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center">Platelet count</td>
<td class="Toprule" align="center">% of full dose</td>
</tr>
<tr>
<td align="center">(x 10<span class="Sup">6</span>/L)</td>
<td align="center"></td>
<td align="center">(x 10<span class="Sup">6</span>/L)</td>
<td align="center"></td>
</tr>
<tr>
<td class="Toprule" align="center">≥1200</td>
<td class="Toprule" align="center">And</td>
<td class="Toprule" align="center">&gt;75,000</td>
<td class="Toprule" align="center">100</td>
</tr>
<tr>
<td align="center">1000 to 1199</td>
<td align="center">Or</td>
<td align="center">50,000 to 75,000</td>
<td align="center">75</td>
</tr>
<tr>
<td align="center">700 to 999</td>
<td align="center">And</td>
<td align="center">≥50,000</td>
<td align="center">50</td>
</tr>
<tr class="Last">
<td align="center">&lt;700</td>
<td align="center">Or</td>
<td align="center">&lt;50,000</td>
<td align="center">Hold</td>
</tr>
</tbody>
</table>
<p>
		     
	In general, for severe (Grade 3 or 4) non-hematological toxicity, except <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, therapy with gemcitabine for injection should be held or decreased by 50% depending on the judgment of the treating physician. For paclitaxel dosage adjustment, see manufacturer’s prescribing information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_2_3_Non_Small_Cell"></a><a name="section-2.3"></a><p></p>
<h2>
<span class="Bold">2.3</span>
		     
	<span class="Bold">Non-Small Cell Lung Cancer</span>
</h2>
<p class="First">
		     
	Two schedules have been investigated and the optimum schedule has not been determined <span class="Italics">[see </span><span class="Italics"><a href="#_14_CLINICAL_STUDIES">Clinical Studies</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_14_3_Non_Small_Cell">14.3</a></span><span class="Italics">)]</span>. With the 4-week schedule, gemcitabine for injection should be administered intravenously at 1000 mg/m<span class="Sup">2</span> over 30 minutes on Days 1, 8, and 15 of each 28-day cycle. Cisplatin should be administered intravenously at 100 mg/m<span class="Sup">2</span> on Day 1 after the infusion of gemcitabine for injection. With the 3-week schedule, gemcitabine for injection should be administered intravenously at 1250 mg/m<span class="Sup">2</span> over 30 minutes on Days 1 and 8 of each 21-day cycle. Cisplatin at a dose of 100 mg/m<span class="Sup">2</span> should be administered intravenously after the infusion of gemcitabine for injection on Day 1. See prescribing information for cisplatin administration and hydration guidelines.</p>
<p><span class="Underline">Dose Modifications </span></p>
<p>
		     
	Dosage adjustments for hematologic toxicity may be required for gemcitabine for injection and for cisplatin. Gemcitabine for injection dosage adjustment for hematological toxicity is based on the granulocyte and platelet counts taken on the day of therapy. Patients receiving gemcitabine for injection should be monitored prior to each dose with a complete blood count (CBC), including differential and platelet counts. If marrow suppression is detected, therapy should be modified or suspended according to the guidelines in Table 3. For cisplatin dosage adjustment, see manufacturer’s prescribing information.</p>
<p>
		     
	In general, for severe (Grade 3 or 4) non-hematological toxicity, except <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, therapy with gemcitabine for injection plus cisplatin should be held or decreased by 50% depending on the judgment of the treating physician. During combination therapy with cisplatin, serum creatinine, serum potassium, serum calcium, and serum magnesium should be carefully monitored (Grade 3/4 serum creatinine toxicity for gemcitabine for injection plus cisplatin was 5% versus 2% for cisplatin alone).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_2_4_Pancreatic_Cancer"></a><a name="section-2.4"></a><p></p>
<h2>
<span class="Bold">2.4</span>
		     
	<span class="Bold">Pancreatic Cancer</span>
</h2>
<p class="First">
		     
	Gemcitabine for injection should be administered by intravenous infusion at a dose of 1000 mg/m<span class="Sup">2</span> over 30 minutes once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles should consist of infusions once weekly for 3 consecutive weeks out of every 4 weeks.</p>
<p><span class="Underline">Dose Modifications </span></p>
<p>
		     
	Dosage adjustment is based upon the degree of hematologic toxicity experienced by the patient <span class="Italics">[see </span><span class="Italics"><a href="#_5_WARNINGS_AND">Warnings and Precautions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_5_2_Hematology">5.2</a></span><span class="Italics">)]</span>. Clearance in women and the elderly is reduced and women were somewhat less able to progress to subsequent cycles <span class="Italics">[see </span><span class="Italics"><a href="#_5_WARNINGS_AND">Warnings and Precautions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_5_2_Hematology">5.2</a></span><span class="Italics">) and </span><span class="Italics"><a href="#_12_CLINICAL_PHARMACOLOGY">Clinical Pharmacology</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_12_3_Pharmacokinetics">12.3</a></span><span class="Italics">)]</span>.</p>
<p>
		     
	Patients receiving gemcitabine for injection should be monitored prior to each dose with a complete blood count (CBC), including differential and platelet count. If marrow suppression is detected, therapy should be modified or suspended according to the guidelines in Table 3.</p>
<table>
<caption><span>Table 3: Dosage Reduction Guidelines</span></caption>
<col width="214">
<col width="135">
<col width="194">
<col width="180">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center">Absolute granulocyte count</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center">Platelet count</td>
<td class="Toprule" align="center">% of full dose</td>
</tr>
<tr>
<td align="center">(x 10<span class="Sup">6</span>/L)</td>
<td align="center"></td>
<td align="center">(x 10<span class="Sup">6</span>/L)</td>
<td align="center"></td>
</tr>
<tr>
<td class="Toprule" align="center">≥1000</td>
<td class="Toprule" align="center">And</td>
<td class="Toprule" align="center">≥100,000</td>
<td class="Toprule" align="center">100</td>
</tr>
<tr>
<td align="center">500 to 999</td>
<td align="center">Or</td>
<td align="center">50,000 to 99,999</td>
<td align="center">75</td>
</tr>
<tr class="Last">
<td align="center">&lt;500</td>
<td align="center">Or</td>
<td align="center">&lt;50,000</td>
<td align="center">Hold</td>
</tr>
</tbody>
</table>
<p>
		     
	Laboratory evaluation of renal and hepatic function, including transaminases and serum creatinine, should be performed prior to initiation of therapy and periodically thereafter. Gemcitabine for injection should be administered with caution in patients with evidence of significant renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> as there is insufficient information from clinical studies to allow clear dose recommendation for these patient populations.</p>
<p>
		     
	Patients treated with gemcitabine for injection who complete an entire cycle of therapy may have the dose for subsequent cycles increased by 25%, provided that the absolute granulocyte count (AGC) and platelet nadirs exceed 1500 x 10<span class="Sup">6</span>/L and 100,000 x 10<span class="Sup">6</span>/L, respectively, and if non-hematologic toxicity has not been greater than WHO Grade 1. If patients tolerate the subsequent course of gemcitabine for injection at the increased dose, the dose for the next cycle can be further increased by 20%, provided again that the AGC and platelet nadirs exceed 1500 x 10<span class="Sup">6</span>/L and 100,000 x 10<span class="Sup">6</span>/L, respectively, and that non-hematologic toxicity has not been greater than WHO Grade 1.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_2_5_Preparation_and"></a><a name="section-2.5"></a><p></p>
<h2>
<span class="Bold">2.5</span>
		     
	<span class="Bold">Preparation and Administration Precautions</span>
</h2>
<p class="First">
		     
	Caution should be exercised in handling and preparing gemcitabine for injection solutions. The use of gloves is recommended. If gemcitabine for injection solution contacts the skin or mucosa, immediately wash the skin thoroughly with soap and water or rinse the mucosa with copious amounts of water. Although acute dermal irritation has not been observed in animal studies, 2 of 3 rabbits exhibited drug-related systemic toxicities (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">nasal discharge</span>, <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>) due to dermal absorption.</p>
<p>
		     
	Procedures for proper handling and disposal of anti-cancer drugs should be considered. Several guidelines on this subject have been published <span class="Italics">[see </span><span class="Italics"><a href="#_15_REFERENCES">References</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_15_REFERENCES">15</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_2_6_Preparation_for"></a><a name="section-2.6"></a><p></p>
<h2>
<span class="Bold">2.6</span>
		     
	<span class="Bold">Preparation for Intravenous Infusion Administration</span>
</h2>
<p class="First">
		     
	The recommended diluent for reconstitution of gemcitabine for injection is 0.9% Sodium Chloride Injection without preservatives. Due to solubility considerations, the maximum concentration for gemcitabine for injection upon reconstitution is 40 mg/mL. Reconstitution at concentrations greater than 40 mg/mL may result in incomplete dissolution, and should be avoided.</p>
<p>
		     
	To reconstitute, add 5 mL of 0.9% Sodium Chloride Injection to the 200-mg vial or 25 mL of 0.9% Sodium Chloride Injection to the 1-g vial. Shake to dissolve. These dilutions each yield a gemcitabine concentration of 38 mg/mL which includes accounting for the displacement volume of the lyophilized powder (0.26 mL for the 200-mg vial or 1.3 mL for the 1-g vial). The total volume upon reconstitution will be 5.26 mL or 26.3 mL, respectively. Complete withdrawal of the vial contents will provide 200 mg or 1 g of gemcitabine, respectively. Prior to administration the appropriate amount of drug must be diluted with 0.9% Sodium Chloride Injection. Final concentrations may be as low as 0.1 mg/mL.</p>
<p>
		     
	Reconstituted gemcitabine for injection is a clear, colorless to light straw-colored solution. After reconstitution with 0.9% Sodium Chloride Injection, the pH of the resulting solution lies in the range of 2.7 to 3.3. The solution should be inspected visually for particulate matter and discoloration prior to administration, whenever solution or container permit. If particulate matter or discoloration is found, do not administer.</p>
<p>
		     
	When prepared as directed, gemcitabine for injection solutions are stable for 24 hours at controlled room temperature 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Discard unused portion. Solutions of reconstituted gemcitabine for injection should not be refrigerated, as crystallization may occur.</p>
<p>
		     
	The compatibility of gemcitabine for injection with other drugs has not been studied. No incompatibilities have been observed with infusion bottles or polyvinyl chloride bags and administration sets.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="_3_DOSAGE_FORMS"></a><a name="section-3"></a><p></p>
<h1>
<span class="Bold">3</span>
		     
	<span class="Bold">DOSAGE FORMS AND STRENGTHS</span>
</h1>
<p class="First">
		     
	Gemcitabine for injection, USP is a white to off-white lyophilized powder available in sterile single-use vials containing 200 mg or 1 g gemcitabine.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="_4_CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<h1>
<span class="Bold">4</span>
		     
	<span class="Bold">CONTRAINDICATIONS</span>
</h1>
<p class="First">
		     
	Gemcitabine for injection is contraindicated in those patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_5_WARNINGS_AND"></a><a name="section-5"></a><p></p>
<h1>
<span class="Bold">5</span>
		     
	<span class="Bold">WARNINGS AND PRECAUTIONS</span>
</h1>
<p class="First">
		     
	Patients receiving therapy with gemcitabine for injection should be monitored closely by a physician experienced in the use of cancer chemotherapeutic agents.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_1_Infusion_Time"></a><a name="section-5.1"></a><p></p>
<h2>
<span class="Bold">5.1</span>
		     
	<span class="Bold">Infusion Time</span>
</h2>
<p class="First">
		     
	Caution — Prolongation of the infusion time beyond 60 minutes and more frequent than weekly dosing have been shown to increase toxicity <span class="Italics">[see </span><span class="Italics"><a href="#_14_CLINICAL_STUDIES">Clinical Studies</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_14_5_Other_Clinical">14.5</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_2_Hematology"></a><a name="section-5.2"></a><p></p>
<h2>
<span class="Bold">5.2</span>
		     
	<span class="Bold">Hematology</span>
</h2>
<p class="First">
		     
	Gemcitabine for injection can suppress bone marrow function as manifested by <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> <span class="Italics">[see </span><span class="Italics"><a href="#_6_ADVERSE_REACTIONS">Adverse Reactions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_6_1_Clinical_Trials">6.1</a></span><span class="Italics">)]</span>, and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is usually the dose-limiting toxicity. Patients should be monitored for <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> during therapy <span class="Italics">[see </span><span class="Italics"><a href="#_2_DOSAGE_AND">Dosage and Administration</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_2_1_Ovarian_Cancer">2.1</a></span><span class="Italics">, </span><span class="Italics"><a href="#_2_2_Breast_Cancer">2.2</a></span><span class="Italics">, </span><span class="Italics"><a href="#_2_3_Non_Small_Cell">2.3</a></span><span class="Italics">, and </span><span class="Italics"><a href="#_2_4_Pancreatic_Cancer">2.4</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_3_Pulmonary"></a><a name="section-5.3"></a><p></p>
<h2>
<span class="Bold">5.3</span>
		     
	<span class="Bold">Pulmonary</span>
</h2>
<p class="First">
		     
	Pulmonary toxicity has been reported with the use of gemcitabine for injection. In cases of severe lung toxicity, gemcitabine for injection therapy should be discontinued immediately and appropriate supportive care measures instituted <span class="Italics">[see </span><span class="Italics"><a href="#_6_ADVERSE_REACTIONS">Adverse Reactions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_6_1_Clinical_Trials">6.1</a></span><span class="Italics"> and </span><span class="Italics"><a href="#_6_2_Post_Marketing_Experience">6.2</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_4_Renal"></a><a name="section-5.4"></a><p></p>
<h2>
<span class="Bold">5.4</span>
		     
	<span class="Bold">Renal</span>
</h2>
<p class="First">
		     
	<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic Uremic Syndrome</span> (HUS) and/or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> have been reported following one or more doses of gemcitabine for injection. <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or requiring dialysis, despite discontinuation of therapy, has been reported. The majority of the cases of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were due to HUS <span class="Italics">[see </span><span class="Italics"><a href="#_6_ADVERSE_REACTIONS">Adverse Reactions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_6_1_Clinical_Trials">6.1</a></span><span class="Italics"> and </span><span class="Italics"><a href="#_6_2_Post_Marketing_Experience">6.2</a></span><span class="Italics">)</span><span class="Italics">]</span>.</p>
<p>
		     
	Gemcitabine for injection should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> as there is insufficient information from clinical studies to allow clear dose recommendation for these patient populations <span class="Italics">[see </span><span class="Italics"><a href="#_8_USE_IN">Use in Specific Populations</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_8_6_Renal">8.6</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_5_Hepatic"></a><a name="section-5.5"></a><p></p>
<h2>
<span class="Bold">5.5</span>
		     
	<span class="Bold">Hepatic</span>
</h2>
<p class="First">
		     
	Serious hepatotoxicity, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients receiving gemcitabine for injection alone or in combination with other potentially hepatotoxic drugs <span class="Italics">[see </span><span class="Italics"><a href="#_6_ADVERSE_REACTIONS">Adverse Reactions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_6_1_Clinical_Trials">6.1</a></span><span class="Italics"> and </span><span class="Italics"><a href="#_6_2_Post_Marketing_Experience">6.2</a></span><span class="Italics">)</span><span class="Italics">]</span>.</p>
<p>
		     
	Gemcitabine for injection should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> as there is insufficient information from clinical studies to allow clear dose recommendation for these patient populations. Administration of gemcitabine for injection in patients with concurrent liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> or a preexisting medical history of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>, or <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">liver cirrhosis</span> may lead to exacerbation of the underlying <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> <span class="Italics">[see </span><span class="Italics"><a href="#_8_USE_IN">Use in Specific Populations</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_8_7_Hepatic">8.7</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="_5_6_Pregnancy"></a><a name="section-5.6"></a><p></p>
<h2>
<span class="Bold">5.6</span>
		     
	<span class="Bold">Pregnancy</span>
</h2>
<p class="First">
		     
	Gemcitabine for injection can cause fetal harm when administered to a pregnant woman. In pre-clinical studies in mice and rabbits, gemcitabine was teratogenic, embryotoxic, and fetotoxic. There are no adequate and well-controlled studies of gemcitabine for injection in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus <span class="Italics">[see </span><span class="Italics"><a href="#_8_USE_IN">Use in Specific Populations</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_8_1_Pregnancy">8.1</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="_5_7_Laboratory_Tests"></a><a name="section-5.7"></a><p></p>
<h2>
<span class="Bold">5.7</span>
		     
	<span class="Bold">Laboratory Tests</span>
</h2>
<p class="First">
		     
	Patients receiving gemcitabine for injection should be monitored prior to each dose with a complete blood count (CBC), including differential and platelet count. Suspension or modification of therapy should be considered when marrow suppression is detected <span class="Italics">[see </span><span class="Italics"><a href="#_2_DOSAGE_AND">Dosage and Administration</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_2_1_Ovarian_Cancer">2.1</a></span><span class="Italics">, </span><span class="Italics"><a href="#_2_2_Breast_Cancer">2.2</a></span><span class="Italics">, </span><span class="Italics"><a href="#_2_3_Non_Small_Cell">2.3</a></span><span class="Italics">, and </span><span class="Italics"><a href="#_2_4_Pancreatic_Cancer">2.4</a></span><span class="Italics">)]</span>.</p>
<p>
		     
	Laboratory evaluation of renal and hepatic function should be performed prior to initiation of therapy and periodically thereafter <span class="Italics">[see </span><span class="Italics"><a href="#_2_DOSAGE_AND">Dosage and Administration</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_2_4_Pancreatic_Cancer">2.4</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_8_Radiation_Therapy"></a><a name="section-5.8"></a><p></p>
<h2>
<span class="Bold">5.8</span>
		     
	<span class="Bold">Radiation Therapy</span>
</h2>
<p class="First">
		     
	A pattern of tissue injury typically associated with radiation toxicity has been reported in association with concurrent and non-concurrent use of gemcitabine for injection.</p>
<p>
		     
	<span class="Underline">Non-concurrent (given &gt;7 days apart)</span> — Analysis of the data does not indicate enhanced toxicity when gemcitabine for injection is administered more than 7 days before or after radiation, other than radiation recall. Data suggest that gemcitabine for injection can be started after the acute effects of radiation have resolved or at least one week after radiation.</p>
<p>
		     
	<span class="Underline">Concurrent (given together or ≤7 days apart)</span> —Preclinical and clinical studies have shown that gemcitabine for injection has radiosensitizing activity. Toxicity associated with this multimodality therapy is dependent on many different factors, including dose of gemcitabine for injection, frequency of gemcitabine for injection administration, dose of radiation, radiotherapy planning technique, the target tissue, and target volume. In a single trial, where gemcitabine for injection at a dose of 1000 mg/m<span class="Sup">2</span> was administered concurrently for up to 6 consecutive weeks with therapeutic thoracic radiation to patients with non-small cell lung cancer, significant toxicity in the form of severe, and potentially life-threatening <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, especially <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> was observed, particularly in patients receiving large volumes of radiotherapy [median treatment volumes 4795 cm<span class="Sup">3</span>]. Subsequent studies have been reported and suggest that gemcitabine for injection administered at lower doses with concurrent radiotherapy has predictable and less severe toxicity. However, the optimum regimen for safe administration of gemcitabine for injection with therapeutic doses of radiation has not yet been determined in all tumor types.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="_6_ADVERSE_REACTIONS"></a><a name="section-6"></a><p></p>
<h1>
<span class="Bold">6</span>
		     
	<span class="Bold">ADVERSE REACTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_6_1_Clinical_Trials"></a><a name="section-6.1"></a><p></p>
<h2>
<span class="Bold">6.1</span>
		     
	<span class="Bold">Clinical Trials Experience</span>
</h2>
<p class="First">
		     
	Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>
		     
	Most adverse reactions are reversible and do not need to result in discontinuation, although doses may need to be withheld or reduced.</p>
<p>
		     
	Gemcitabine has been used in a wide variety of malignancies, both as a single-agent and in combination with other cytotoxic drugs.</p>
<p><span class="Underline">Single-Agent Use:</span></p>
<p>
		     
	<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> is the principal dose-limiting toxicity with gemcitabine therapy. Dosage adjustments for hematologic toxicity are frequently needed <span class="Italics">[see </span><span class="Italics"><a href="#_2_DOSAGE_AND">Dosage and Administration</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_2_1_Ovarian_Cancer">2.1</a></span><span class="Italics">, </span><span class="Italics"><a href="#_2_2_Breast_Cancer">2.2</a></span><span class="Italics">, </span><span class="Italics"><a href="#_2_3_Non_Small_Cell">2.3</a></span><span class="Italics">, and </span><span class="Italics"><a href="#_2_4_Pancreatic_Cancer">2.4</a></span><span class="Italics">)</span><span class="Italics">]</span>.</p>
<p>
		     
	The data in Table 4 are based on 979 patients receiving gemcitabine as a single-agent administered weekly as a 30-minute infusion for treatment of a wide variety of malignancies. The gemcitabine starting doses ranged from 800 to 1250 mg/m<span class="Sup">2</span>. Data are also shown for the subset of patients with pancreatic cancer treated in 5 clinical studies. The frequency of all grades and severe (WHO Grade 3 or 4) adverse reactions were generally similar in the single-agent safety database of 979 patients and the subset of patients with pancreatic cancer. Adverse reactions reported in the single-agent safety database resulted in discontinuation of gemcitabine therapy in about 10% of patients. In the comparative trial in pancreatic cancer, the discontinuation rate for adverse reactions was 14.3% for the gemcitabine arm and 4.8% for the 5-FU arm. All WHO-graded laboratory adverse reactions are listed in Table 4, regardless of causality. Non-laboratory adverse reactions listed in Table 4 or discussed below were those reported, regardless of causality, for at least 10% of all patients, except the categories of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span>, Allergic, and Cardiovascular and certain specific adverse reactions under the Renal, Pulmonary, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> categories.</p>
<table>
<caption><span>Table 4: Selected WHO-Graded Adverse Reactions in Patients Receiving Single-Agent Gemcitabine WHO Grades (% incidence)<span class="Sup">a</span></span></caption>
<col width="210">
<col width="49">
<col width="72">
<col width="72">
<col width="84">
<col width="71">
<col width="70">
<col width="121">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">All Patients</span><span class="Bold"><span class="Sup">b</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">Pancreatic Cancer</span><span class="Bold"><br>Patients</span><span class="Bold"><span class="Sup">c</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center">
<span class="Bold">Discontinuations</span><span class="Bold"><br>(%)</span><span class="Bold"><span class="Sup">d</span></span>
</td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule Toprule" align="center">All Grades</td>
<td class="Lrule Rrule Toprule" align="center">Grade 3</td>
<td class="Lrule Rrule Toprule" align="center">Grade 4</td>
<td class="Lrule Rrule Toprule" align="center">All Grades</td>
<td class="Lrule Rrule Toprule" align="center">Grade 3</td>
<td class="Lrule Rrule Toprule" align="center">Grade 4</td>
<td class="Lrule Rrule Toprule" align="center">All Patients</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
<span class="Bold">Laboratory</span><span class="Bold"><span class="Sup">e</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Hematologic</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Lrule Rrule" align="center">68</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">73</td>
<td class="Lrule Rrule" align="center">8</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Lrule Rrule" align="center">62</td>
<td class="Lrule Rrule" align="center">9</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">64</td>
<td class="Lrule Rrule" align="center">8</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Lrule Rrule" align="center">63</td>
<td class="Lrule Rrule" align="center">19</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">61</td>
<td class="Lrule Rrule" align="center">17</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Lrule Rrule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Lrule Rrule" align="center">24</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">36</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
		     
	Hepatic</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	ALT</td>
<td class="Lrule Rrule" align="center">68</td>
<td class="Lrule Rrule" align="center">8</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">72</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	AST</td>
<td class="Lrule Rrule" align="center">67</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">78</td>
<td class="Lrule Rrule" align="center">12</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	Alkaline Phosphatase</td>
<td class="Lrule Rrule" align="center">55</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">77</td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	Bilirubin</td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">26</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
		     
	Renal</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></td>
<td class="Lrule Rrule" align="center">45</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">32</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td class="Lrule Rrule" align="center">35</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">23</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	BUN</td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">15</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	Creatinine</td>
<td class="Lrule Rrule" align="center">8</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
<span class="Bold">Non-laboratory</span><span class="Bold"><span class="Sup">f</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">69</td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">71</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Lrule Rrule" align="center">41</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">38</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Lrule Rrule" align="center">30</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">28</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Lrule Rrule" align="center">23</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule" align="center">19</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">30</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></td>
<td class="Lrule Rrule" align="center">17</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Lrule Rrule" align="center">15</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Lrule Rrule" align="center">11</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Lrule Rrule" align="center">11</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">11</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span></td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Grade based on criteria from the World Health Organization (WHO).</p>
<p><span class="Sup">b</span> N=699 to 974; all patients with laboratory or non-laboratory data.</p>
<p><span class="Sup">c</span> N=161 to 241; all pancreatic cancer patients with laboratory or non-laboratory data.</p>
<p><span class="Sup">d</span> N=979.</p>
<p><span class="Sup">e</span> Regardless of causality.</p>
<p><span class="Sup">f</span> Table includes non-laboratory data with incidence for all patients ≥10%. For approximately 60% of the patients, non-laboratory adverse reactions were graded only if assessed to be possibly drug-related.</p>
<p>
		     
	<span class="Italics">Hematologic </span>— In studies in pancreatic cancer <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is the dose-limiting toxicity with gemcitabine, but &lt;1% of patients discontinued therapy for either <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. Red blood cell transfusions were required by 19% of patients. The incidence of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> was less than 1%. <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span> or mild blood loss (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>), from any cause, was reported in 16% of patients; less than 1% of patients required platelet transfusions. Patients should be monitored for <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> during gemcitabine therapy and dosage modified or suspended according to the degree of hematologic toxicity <span class="Italics">[see </span><span class="Italics"><a href="#_2_DOSAGE_AND">Dosage and Administration</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_2_1_Ovarian_Cancer">2.1</a></span><span class="Italics">, </span><span class="Italics"><a href="#_2_2_Breast_Cancer">2.2</a></span><span class="Italics">, </span><span class="Italics"><a href="#_2_3_Non_Small_Cell">2.3</a></span><span class="Italics">, and </span><span class="Italics"><a href="#_2_4_Pancreatic_Cancer">2.4</a></span><span class="Italics">)</span><span class="Italics">]</span>.</p>
<p>
		     
	<span class="Italics">Gastrointestinal </span>— <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> were commonly reported (69%) but were usually of mild to moderate severity. Severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (WHO Grade 3/4) occurred in &lt;15% of patients. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> was reported by 19% of patients, and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> by 11% of patients.</p>
<p>
		     
	<span class="Italics">Hepatic </span>— In clinical trials, gemcitabine was associated with transient elevations of one or both serum transaminases in approximately 70% of patients, but there was no evidence of increasing hepatic toxicity with either longer duration of exposure to gemcitabine or with greater total cumulative dose. Serious hepatotoxicity, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported very rarely in patients receiving gemcitabine alone or in combination with other potentially hepatotoxic drugs <span class="Italics">[see </span><span class="Italics"><a href="#_6_ADVERSE_REACTIONS">Adverse Reactions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_6_2_Post_Marketing_Experience">6.2</a></span><span class="Italics">)]</span>.</p>
<p>
		     
	<span class="Italics">Renal</span> — In clinical trials, mild <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> were commonly reported. Clinical findings consistent with the <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic Uremic Syndrome</span> (HUS) were reported in 6 of 2429 patients (0.25%) receiving gemcitabine in clinical trials. Four patients developed HUS on gemcitabine therapy, 2 immediately post-therapy. The diagnosis of HUS should be considered if the patient develops <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> with evidence of microangiopathic <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, elevation of bilirubin or LDH, <span class="product-label-link" type="condition" conceptid="4261785" conceptname="Reticulocytosis">reticulocytosis</span>, severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and/or evidence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (elevation of serum creatinine or BUN). Gemcitabine therapy should be discontinued immediately. <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> may not be reversible even with discontinuation of therapy and dialysis may be required <span class="Italics">[see </span><span class="Italics"><a href="#_6_ADVERSE_REACTIONS">Adverse Reactions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_6_2_Post_Marketing_Experience">6.2</a></span><span class="Italics">)</span><span class="Italics">]</span>.</p>
<p>
		     
	<span class="Italics"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </span>— The overall incidence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> was 41%. This is in contrast to the incidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (16%) and indicates that gemcitabine may cause <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> in the absence of clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> was frequently associated with other flu-like symptoms and was usually mild and clinically manageable.</p>
<p>
		     
	<span class="Italics"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </span>— <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> was reported in 30% of patients. The <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was typically a macular or finely granular maculopapular pruritic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span> of mild to moderate severity involving the trunk and extremities. <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> was reported for 13% of patients.</p>
<p>
		     
	<span class="Italics">Pulmonary</span> — In clinical trials, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, unrelated to underlying disease, has been reported in association with gemcitabine therapy. <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> was occasionally accompanied by <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. Pulmonary toxicity has been reported with the use of gemcitabine <span class="Italics">[see </span><span class="Italics"><a href="#_6_ADVERSE_REACTIONS">Adverse Reactions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_6_2_Post_Marketing_Experience">6.2</a></span><span class="Italics">)</span><span class="Italics">]</span>. The etiology of these effects is unknown. If such effects develop, gemcitabine should be discontinued. Early use of supportive care measures may help ameliorate these conditions.</p>
<p>
		     
	<span class="Italics"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </span>— <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> (13%), <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (20%), and <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span> (&lt;1%) were reported. Less than 1% of patients discontinued due to <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p>
		     
	<span class="Italics">Flu-like Symptoms </span>— “Flu syndrome? was reported for 19% of patients. Individual symptoms of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> were commonly reported. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> were also reported frequently as isolated symptoms. <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> were reported infrequently. Less than 1% of patients discontinued due to flu-like symptoms.</p>
<p>
		     
	<span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </span>— <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> were reported for 16% of patients. <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> was rarely reported (&lt;1%).</p>
<p>
		     
	<span class="Italics"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> </span>— <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span>, usually minimal, was reported by 15% of patients.</p>
<p>
		     
	<span class="Italics"><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span> </span>— There was a 10% incidence of mild <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> and a &lt;1% rate of severe <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>.</p>
<p>
		     
	<span class="Italics"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> </span>— Injection-site related events were reported for 4% of patients. There were no reports of <span class="product-label-link" type="condition" conceptid="4318393" conceptname="Injection site necrosis">injection site necrosis</span>. Gemcitabine is not a vesicant.</p>
<p>
		     
	<span class="Italics">Allergic </span>— <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> was reported for less than 2% of patients. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span> has been reported rarely. Gemcitabine should not be administered to patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this drug <span class="Italics">[see </span><span class="Italics"><a href="#_4_CONTRAINDICATIONS">Contraindications</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_4_CONTRAINDICATIONS">4</a></span><span class="Italics">)]</span>.</p>
<p>
		     
	<span class="Italics">Cardiovascular</span> — During clinical trials, 2% of patients discontinued therapy with gemcitabine due to cardiovascular events such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Many of these patients had a prior history of cardiovascular disease <span class="Italics">[see </span><span class="Italics"><a href="#_6_ADVERSE_REACTIONS">Adverse Reactions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_6_2_Post_Marketing_Experience">6.2</a></span><span class="Italics">)]</span>.</p>
<p><span class="Underline">Combination Use in Non-Small Cell Lung Cancer: </span></p>
<p>
		     
	In the gemcitabine plus cisplatin versus cisplatin study, dose adjustments occurred with 35% of gemcitabine injections and 17% of cisplatin injections on the combination arm, versus 6% on the cisplatin-only arm. Dose adjustments were required in greater than 90% of patients on the combination, versus 16% on cisplatin. Study discontinuations for possibly drug-related adverse reactions occurred in 15% of patients on the combination arm and 8% of patients on the cisplatin arm. With a median of 4 cycles of gemcitabine plus cisplatin treatment, 94 of 262 patients (36%) experienced a total of 149 hospitalizations due to possibly treatment-related adverse reactions. With a median of 2 cycles of cisplatin treatment, 61 of 260 patients (23%) experienced 78 hospitalizations due to possibly treatment-related adverse reactions.</p>
<p>
		     
	In the gemcitabine plus cisplatin versus etoposide plus cisplatin study, dose adjustments occurred with 20% of gemcitabine injections and 16% of cisplatin injections in the gemcitabine plus cisplatin arm compared with 20% of etoposide injections and 15% of cisplatin injections in the etoposide plus cisplatin arm. With a median of 5 cycles of gemcitabine plus cisplatin treatment, 15 of 69 patients (22%) experienced 15 hospitalizations due to possibly treatment-related adverse reactions. With a median of 4 cycles of etoposide plus cisplatin treatment, 18 of 66 patients (27%) experienced 22 hospitalizations due to possibly treatment-related adverse reactions. In patients who completed more than one cycle, dose adjustments were reported in 81% of the gemcitabine plus cisplatin patients, compared with 68% on the etoposide plus cisplatin arm. Study discontinuations for possibly drug-related adverse reactions occurred in 14% of patients on the gemcitabine plus cisplatin arm and in 8% of patients on the etoposide plus cisplatin arm. The incidence of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> was increased in frequency with gemcitabine plus cisplatin treatment (~90%) compared to that with the gemcitabine monotherapy (~60%). With combination therapy gemcitabine dosage adjustments for hematologic toxicity were required more often while cisplatin dose adjustments were less frequently required.</p>
<p>
		     
	Table 5 presents the safety data from the gemcitabine plus cisplatin versus cisplatin study in non-small cell lung cancer. The NCI Common Toxicity Criteria (CTC) were used. The two-drug combination was more myelosuppressive with 4 (1.5%) possibly treatment-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, including 3 resulting from <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and one case of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> associated with <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to treatment were reported on the cisplatin arm. Nine cases of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> were reported on the combination therapy arm compared to 2 on the cisplatin arm. More patients required RBC and platelet transfusions on the gemcitabine plus cisplatin arm.</p>
<p>
		     
	<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> occurred more frequently on the combination arm, and in 4 possibly treatment-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> was observed. <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> was reported in 4% of patients on the gemcitabine plus cisplatin arm compared to 1% on the cisplatin arm. Platelet transfusions were required in 21% of patients on the combination arm and &lt;1% of patients on the cisplatin arm. Hemorrhagic events occurred in 14% of patients on the combination arm and 4% on the cisplatin arm. However, severe hemorrhagic events were rare. Red blood cell transfusions were required in 39% of the patients on the gemcitabine plus cisplatin arm, versus 13% on the cisplatin arm. The data suggest cumulative <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> with continued gemcitabine plus cisplatin use.</p>
<p>
		     
	<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> despite the use of antiemetics occurred more often with gemcitabine plus cisplatin therapy (78%) than with cisplatin alone (71%). In studies with single-agent gemcitabine, a lower incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (58% to 69%) was reported. Renal function abnormalities, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, neuromotor, neurocortical, and neurocerebellar toxicity occurred more often with gemcitabine plus cisplatin than with cisplatin monotherapy. Neurohearing toxicity was similar on both arms.</p>
<p>
		     
	Cardiac dysrrhythmias of Grade 3 or greater were reported in 7 (3%) patients treated with gemcitabine plus cisplatin compared to one (&lt;1%) Grade 3 dysrrhythmia reported with cisplatin therapy. <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> were associated with one Grade 4 <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> on the gemcitabine plus cisplatin combination arm.</p>
<p>
		     
	Table 6 presents data from the randomized study of gemcitabine plus cisplatin versus etoposide plus cisplatin in 135 patients with NSCLC. One <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (1.5%) was reported on the gemcitabine plus cisplatin arm due to <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> associated with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> which was possibly treatment-related. No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> related to treatment occurred on the etoposide plus cisplatin arm. The overall incidence of Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> on the gemcitabine plus cisplatin arm was less than on the etoposide plus cisplatin arm (28% versus 56%). <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> was experienced by 2% of patients on both treatment arms. Grade 3 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and Grade 3/4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> were more common on the gemcitabine plus cisplatin arm. RBC transfusions were given to 29% of the patients who received gemcitabine plus cisplatin versus 21% of patients who received etoposide plus cisplatin. Platelet transfusions were given to 3% of the patients who received gemcitabine plus cisplatin versus 8% of patients who received etoposide plus cisplatin. Grade 3/4 <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> were also more common on the gemcitabine plus cisplatin arm. On the gemcitabine plus cisplatin arm, 7% of participants were hospitalized due to <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> compared to 12% on the etoposide plus cisplatin arm. More than twice as many patients had dose reductions or omissions of a scheduled dose of gemcitabine as compared to etoposide, which may explain the differences in the incidence of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> between treatment arms. <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span> was reported by 3% of patients on the gemcitabine plus cisplatin arm with none reported on the comparator arm. Eight patients (12%) on the gemcitabine plus cisplatin arm reported <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> compared to one patient (2%) on the etoposide plus cisplatin arm.</p>
<table>
<caption><span>Table 5: Selected CTC-Graded Adverse Reactions From Comparative Trial of Gemcitabine Plus Cisplatin Versus Single-Agent Cisplatin in NSCLC CTC Grades (% incidence)<span class="Sup">a</span></span></caption>
<col width="264">
<col width="90">
<col width="84">
<col width="84">
<col width="90">
<col width="66">
<col width="68">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">Gem</span><span class="Bold">citabine</span><span class="Bold"> plus Cisplatin</span><span class="Bold"><span class="Sup">b</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">Cisplatin</span><span class="Bold"><span class="Sup">c</span></span>
</td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule Toprule" align="center">All Grades</td>
<td class="Lrule Rrule Toprule" align="center">Grade 3</td>
<td class="Lrule Rrule Toprule" align="center">Grade 4</td>
<td class="Lrule Rrule Toprule" align="center">All Grades</td>
<td class="Lrule Rrule Toprule" align="center">Grade 3</td>
<td class="Lrule Rrule Toprule" align="center">Grade 4</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
<span class="Bold">Laboratory</span><span class="Bold"><span class="Sup">d</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Hematologic</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Lrule Rrule" align="center">89</td>
<td class="Lrule Rrule" align="center">22</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">67</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	RBC Transfusion<span class="Sup">e</span>
</td>
<td class="Lrule Rrule" align="center">39</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Lrule Rrule" align="center">82</td>
<td class="Lrule Rrule" align="center">35</td>
<td class="Lrule Rrule" align="center">11</td>
<td class="Lrule Rrule" align="center">25</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Lrule Rrule" align="center">79</td>
<td class="Lrule Rrule" align="center">22</td>
<td class="Lrule Rrule" align="center">35</td>
<td class="Lrule Rrule" align="center">20</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Lrule Rrule" align="center">85</td>
<td class="Lrule Rrule" align="center">25</td>
<td class="Lrule Rrule" align="center">25</td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Platelet Transfusions<span class="Sup">e</span>
</td>
<td class="Lrule Rrule" align="center">21</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">Lymphocytes</span></td>
<td class="Lrule Rrule" align="center">75</td>
<td class="Lrule Rrule" align="center">25</td>
<td class="Lrule Rrule" align="center">18</td>
<td class="Lrule Rrule" align="center">51</td>
<td class="Lrule Rrule" align="center">12</td>
<td class="Lrule Rrule" align="center">5</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
		     
	Hepatic</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	Transaminase</td>
<td class="Lrule Rrule" align="center">22</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	Alkaline Phosphatase</td>
<td class="Lrule Rrule" align="center">19</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
		     
	Renal</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></td>
<td class="Lrule Rrule" align="center">23</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">18</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td class="Lrule Rrule" align="center">15</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	Creatinine</td>
<td class="Lrule Rrule" align="center">38</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">31</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
		     
	Other Laboratory</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
<td class="Lrule Rrule" align="center">30</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">23</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></td>
<td class="Lrule Rrule" align="center">30</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">17</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></td>
<td class="Lrule Rrule" align="center">18</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
<span class="Bold">Non-laboratory</span><span class="Bold"><span class="Sup">f</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule" align="center">93</td>
<td class="Lrule Rrule" align="center">25</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">87</td>
<td class="Lrule Rrule" align="center">20</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">78</td>
<td class="Lrule Rrule" align="center">11</td>
<td class="Lrule Rrule" align="center">12</td>
<td class="Lrule Rrule" align="center">71</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">9</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Lrule Rrule" align="center">53</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">33</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Neuro Motor</td>
<td class="Lrule Rrule" align="center">35</td>
<td class="Lrule Rrule" align="center">12</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">15</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Neuro Hearing</td>
<td class="Lrule Rrule" align="center">25</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">21</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule" align="center">24</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Neuro Sensory</td>
<td class="Lrule Rrule" align="center">23</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">18</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Lrule Rrule" align="center">18</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">12</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Neuro Cortical</td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">9</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Neuro Mood</td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Local</td>
<td class="Lrule Rrule" align="center">15</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Neuro <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule Rrule" align="center">14</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Lrule Rrule" align="center">14</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></td>
<td class="Lrule Rrule" align="center">14</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Lrule Rrule" align="center">12</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">11</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Lrule Rrule" align="center">12</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Lrule Rrule" align="center">11</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Grade based on Common Toxicity Criteria (CTC). Table includes data for adverse reactions with incidence ≥10% in either arm.</p>
<p><span class="Sup">b</span> N=217 to 253; all gemcitabine plus cisplatin patients with laboratory or non-laboratory data. Gemcitabine at 1000 mg/m<span class="Sup">2</span> on Days 1, 8, and 15 and cisplatin at 100 mg/m<span class="Sup">2</span> on Day 1 every 28 days.</p>
<p><span class="Sup">c</span> N=213 to 248; all cisplatin patients with laboratory or non-laboratory data. Cisplatin at 100 mg/m<span class="Sup">2</span> on Day 1 every 28 days.</p>
<p><span class="Sup">d</span> Regardless of causality.</p>
<p><span class="Sup">e</span> Percent of patients receiving transfusions. Percent transfusions are not CTC-graded events.</p>
<p><span class="Sup">f</span> Non-laboratory events were graded only if assessed to be possibly drug-related.</p>
<table>
<caption><span>Table 6: Selected WHO-Graded Adverse Reactions From Comparative Trial of Gemcitabine Plus Cisplatin Versus Etoposide Plus Cisplatin in NSCLC WHO Grades (% incidence)<span class="Sup">a</span></span></caption>
<col width="262">
<col width="90">
<col width="66">
<col width="66">
<col width="90">
<col width="78">
<col width="68">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">Gemcitabine </span><span class="Bold">plus Cisplatin</span><span class="Bold"><span class="Sup">b</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">Etoposide plus Cisplatin</span><span class="Bold"><span class="Sup">c</span></span>
</td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule Toprule" align="center">All Grades</td>
<td class="Lrule Rrule Toprule" align="center">Grade 3</td>
<td class="Lrule Rrule Toprule" align="center">Grade 4</td>
<td class="Lrule Rrule Toprule" align="center">All Grades</td>
<td class="Lrule Rrule Toprule" align="center">Grade 3</td>
<td class="Lrule Rrule Toprule" align="center">Grade 4</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
<span class="Bold">Laboratory</span><span class="Bold"><span class="Sup">d</span></span><span class="Bold"> </span>
</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Hematologic</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Lrule Rrule" align="center">88</td>
<td class="Lrule Rrule" align="center">22</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">77</td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	RBC Transfusions<span class="Sup">e</span>
</td>
<td class="Lrule Rrule" align="center">29</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">21</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Lrule Rrule" align="center">86</td>
<td class="Lrule Rrule" align="center">26</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">87</td>
<td class="Lrule Rrule" align="center">36</td>
<td class="Lrule Rrule" align="center">7</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Lrule Rrule" align="center">88</td>
<td class="Lrule Rrule" align="center">36</td>
<td class="Lrule Rrule" align="center">28</td>
<td class="Lrule Rrule" align="center">87</td>
<td class="Lrule Rrule" align="center">20</td>
<td class="Lrule Rrule" align="center">56</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Lrule Rrule" align="center">81</td>
<td class="Lrule Rrule" align="center">39</td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Lrule Rrule" align="center">45</td>
<td class="Lrule Rrule" align="center">8</td>
<td class="Lrule Rrule" align="center">5</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Platelet Transfusions<span class="Sup">e</span>
</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule" align="center">8</td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
		     
	Hepatic</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	ALT</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">12</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	AST</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">11</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	Alkaline Phosphatase</td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">11</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	Bilirubin</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
		     
	Renal</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></td>
<td class="Lrule Rrule" align="center">12</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td class="Lrule Rrule" align="center">22</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	BUN</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	Creatinine</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
<span class="Bold">Non-laboratory</span><span class="Bold"><span class="Sup">f,g</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">96</td>
<td class="Lrule Rrule" align="center">35</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">86</td>
<td class="Lrule Rrule" align="center">19</td>
<td class="Lrule Rrule" align="center">7</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule" align="center">14</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></td>
<td class="Lrule Rrule" align="center">9</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Lrule Rrule" align="center">28</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">21</td>
<td class="Lrule Rrule" align="center">8</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Lrule Rrule" align="center">77</td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">92</td>
<td class="Lrule Rrule" align="center">51</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Lrule Rrule" align="center">20</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">18</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span></td>
<td class="Lrule Rrule" align="center">38</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Grade based on criteria from the World Health Organization (WHO).</p>
<p><span class="Sup">b</span> N=67 to 69; all gemcitabine plus cisplatin patients with laboratory or non-laboratory data. Gemcitabine at 1250 mg/m<span class="Sup">2</span> on Days 1 and 8 and cisplatin at 100 mg/m<span class="Sup">2</span> on Day 1 every 21 days.</p>
<p><span class="Sup">c</span> N=57 to 63; all cisplatin plus etoposide patients with laboratory or non-laboratory data. Cisplatin at 100 mg/m<span class="Sup">2</span> on Day 1 and intravenous etoposide at 100 mg/m<span class="Sup">2</span> on Days 1, 2, and 3 every 21 days.</p>
<p><span class="Sup">d</span> Regardless of causality.</p>
<p><span class="Sup">e</span> Percent of patients receiving transfusions. Percent transfusions are not WHO-graded events.</p>
<p><span class="Sup">f</span> Non-laboratory events were graded only if assessed to be possibly drug-related.</p>
<p><span class="Sup">g</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> data were not collected.</p>
<p><span class="Underline">Combination Use in Breast Cancer: </span></p>
<p>
		     
	In the gemcitabine plus paclitaxel versus paclitaxel study, dose reductions occurred with 8% of gemcitabine injections and 5% of paclitaxel injections on the combination arm, versus 2% on the paclitaxel arm. On the combination arm, 7% of gemcitabine doses were omitted and &lt;1% of paclitaxel doses were omitted, compared to &lt;1% of paclitaxel doses on the paclitaxel arm. A total of 18 patients (7%) on the gemcitabine plus paclitaxel arm and 12 (5%) on the paclitaxel arm discontinued the study because of adverse reactions. There were two <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> on study or within 30 days after study drug discontinuation that were possibly drug-related, one on each arm.</p>
<p>
		     
	Table 7 presents the safety data occurrences of ≥10% (all grades) from the gemcitabine plus paclitaxel versus paclitaxel study in breast cancer.</p>
<table>
<caption><span>Table 7: Adverse Reactions From Comparative Trial of Gemcitabine Plus Paclitaxel Versus Single-Agent Paclitaxel in Breast Cancer<span class="Sup">a</span> CTC Grades (% incidence)</span></caption>
<col width="257">
<col width="90">
<col width="66">
<col width="72">
<col width="84">
<col width="84">
<col width="68">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">Gem</span><span class="Bold">citabine</span><span class="Bold"> plus Pac</span><span class="Bold">l</span><span class="Bold">itaxel</span><br><span class="Bold">(N=262)</span>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">Pac</span><span class="Bold">l</span><span class="Bold">itaxel</span><span class="Bold"><br>(N=259)</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule Toprule" align="center">All Grades</td>
<td class="Lrule Rrule Toprule" align="center">Grade 3</td>
<td class="Lrule Rrule Toprule" align="center">Grade 4</td>
<td class="Lrule Rrule Toprule" align="center">All Grades</td>
<td class="Lrule Rrule Toprule" align="center">Grade 3</td>
<td class="Lrule Rrule Toprule" align="center">Grade 4</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
<span class="Bold">Laboratory</span><span class="Bold"><span class="Sup">b</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Hematologic</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Lrule Rrule" align="center">69</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">51</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Lrule Rrule" align="center">69</td>
<td class="Lrule Rrule" align="center">31</td>
<td class="Lrule Rrule" align="center">17</td>
<td class="Lrule Rrule" align="center">31</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">7</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Lrule Rrule" align="center">26</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Lrule Rrule" align="center">21</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">12</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
		     
	Hepatobiliary</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	ALT</td>
<td class="Lrule Rrule" align="center">18</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	AST</td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
<span class="Bold">Non-laboratory</span><span class="Bold"><span class="Sup">c</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Lrule Rrule" align="center">90</td>
<td class="Lrule Rrule" align="center">14</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">92</td>
<td class="Lrule Rrule" align="center">19</td>
<td class="Lrule Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>-sensory</td>
<td class="Lrule Rrule" align="center">64</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">58</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule" align="center">50</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">31</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule Rrule" align="center">40</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">28</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Lrule Rrule" align="center">33</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">33</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">29</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">15</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Lrule Rrule" align="center">24</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">22</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule" align="center">20</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Lrule Rrule" align="center">17</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">12</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>-motor</td>
<td class="Lrule Rrule" align="center">15</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>/<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span></td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">8</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>/<span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span></td>
<td class="Lrule Rrule" align="center">11</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Grade based on Common Toxicity Criteria (CTC) Version 2.0 (all grades ≥10%).</p>
<p><span class="Sup">b</span> Regardless of causality.</p>
<p><span class="Sup">c</span> Non-laboratory events were graded only if assessed to be possibly drug-related.</p>
<p>
		     
	The following are the clinically relevant adverse reactions that occurred in &gt;1% and &lt;10% (all grades) of patients on either arm. In parentheses are the incidences of Grade 3 and 4 adverse reactions (gemcitabine plus paclitaxel versus paclitaxel): <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (5.0% versus 1.2%), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (0.8% versus 0.8%), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (1.9% versus 0), and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (0 versus 0.8%).</p>
<p>
		     
	No differences in the incidence of laboratory and non-laboratory events were observed in patients 65 years or older, as compared to patients younger than 65.</p>
<p><span class="Underline">Combination Use in Ovarian Cancer: </span></p>
<p>
		     
	In the gemcitabine plus carboplatin versus carboplatin study, dose reductions occurred with 10.4% of gemcitabine injections and 1.8% of carboplatin injections on the combination arm, versus 3.8% on the carboplatin alone arm. On the combination arm, 13.7% of gemcitabine doses were omitted and 0.2% of carboplatin doses were omitted, compared to 0% of carboplatin doses on the carboplatin alone arm. There were no differences in discontinuations due to adverse reactions between arms (10.9% versus 9.8%, respectively).</p>
<p>
		     
	Table 8 presents the adverse reactions (all grades) occurring in ≥10% of patients in the ovarian cancer study.</p>
<table>
<caption><span>Table 8: Adverse Reactions From Comparative Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Carboplatin in Ovarian Cancer<span class="Sup">a</span> CTC Grades (% incidence)</span></caption>
<col width="269">
<col width="96">
<col width="66">
<col width="72">
<col width="84">
<col width="66">
<col width="68">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">Gem</span><span class="Bold">citabine</span><span class="Bold"> plus Carboplatin</span><span class="Bold"><br>(N=175)</span>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">Carboplatin</span><span class="Bold"><br>(N=174)</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule Toprule" align="center">All Grades</td>
<td class="Lrule Rrule Toprule" align="center">Grade 3</td>
<td class="Lrule Rrule Toprule" align="center">Grade 4</td>
<td class="Lrule Rrule Toprule" align="center">All Grades</td>
<td class="Lrule Rrule Toprule" align="center">Grade 3</td>
<td class="Lrule Rrule Toprule" align="center">Grade 4</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
<span class="Bold">Laboratory</span><span class="Bold"><span class="Sup">b</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Hematologic</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Lrule Rrule" align="center">90</td>
<td class="Lrule Rrule" align="center">42</td>
<td class="Lrule Rrule" align="center">29</td>
<td class="Lrule Rrule" align="center">58</td>
<td class="Lrule Rrule" align="center">11</td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Lrule Rrule" align="center">86</td>
<td class="Lrule Rrule" align="center">22</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">75</td>
<td class="Lrule Rrule" align="center">9</td>
<td class="Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Lrule Rrule" align="center">86</td>
<td class="Lrule Rrule" align="center">48</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center">70</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Lrule Rrule" align="center">78</td>
<td class="Lrule Rrule" align="center">30</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center">57</td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	RBC Transfusions<span class="Sup">c</span>
</td>
<td class="Lrule Rrule" align="center">38</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">15</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	
		     
	Platelet Transfusions<span class="Sup">c</span>
</td>
<td class="Lrule Rrule" align="center">9</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
<span class="Bold">Non-laboratory</span><span class="Bold"><span class="Sup">b</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule" align="center">69</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">61</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Lrule Rrule" align="center">49</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">17</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">46</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">36</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Lrule Rrule" align="center">42</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">37</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule Rrule" align="center">40</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">32</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>-sensory</td>
<td class="Lrule Rrule" align="center">29</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">27</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule" align="center">25</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">14</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>/<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span></td>
<td class="Lrule Rrule" align="center">22</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule">
		     
	<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Lrule Rrule" align="center">0</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Grade based on Common Toxicity Criteria (CTC) Version 2.0 (all grades ≥10%).</p>
<p><span class="Sup">b</span> Regardless of causality.</p>
<p><span class="Sup">c</span> Percent of patients receiving transfusions. Transfusions are not CTC-graded events. Blood transfusions included both packed red blood cells and whole blood.</p>
<p>
		     
	In addition to blood product transfusions as listed in Table 8, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> was also managed with hematopoietic agents. These agents were administered more frequently with combination therapy than with monotherapy (granulocyte growth factors: 23.6% and 10.1%, respectively; erythropoietic agents: 7.3% and 3.9%, respectively).</p>
<p>
		     
	The following are the clinically relevant adverse reactions, regardless of causality, that occurred in &gt;1% and &lt;10% (all grades) of patients on either arm. In parentheses are the incidences of Grade 3 and 4 adverse reactions (gemcitabine plus carboplatin versus carboplatin): AST or ALT elevation (0 versus 1.2%), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (3.4% versus 2.9%), <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (1.1% versus 0), hemorrhagic event (2.3% versus 1.1%), <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (2.3% versus 2.9%), motor <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> (1.1% versus 0.6%), and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>/<span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span> (0.6% versus 0).</p>
<p>
		     
	No differences in the incidence of laboratory and non-laboratory events were observed in patients 65 years or older, as compared to patients younger than 65.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_6_2_Post_Marketing_Experience"></a><a name="section-6.2"></a><p></p>
<h2>
<span class="Bold">6.2</span><span class="Bold">
		     
	Post-Marketing Experience</span>
</h2>
<p class="First">
		     
	The following adverse reactions have been identified during post-approval use of gemcitabine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>
		     
	These adverse reactions have occurred after gemcitabine single-agent use and gemcitabine in combination with other cytotoxic agents. Decisions to include these events are based on the seriousness of the event, frequency of reporting, or potential causal connection to gemcitabine.</p>
<p>
		     
	<span class="Italics">Cardiovascular </span>— <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been reported very rarely with the use of gemcitabine. <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, predominantly supraventricular in nature, have been reported very rarely.</p>
<p>
		     
	<span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span> </span>— Clinical signs of peripheral <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> have been reported very rarely.</p>
<p>
		     
	<span class="Italics">Skin </span>— <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span> and non-serious <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> in the absence of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> have been rarely reported. Severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, including <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span> and bullous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>, have been reported very rarely.</p>
<p>
		     
	<span class="Italics">Hepatic </span>— Increased liver function tests including elevations in <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST), <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase, and bilirubin levels have been reported rarely. Serious hepatotoxicity including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has been reported very rarely in patients receiving gemcitabine alone or in combination with other potentially hepatotoxic drugs. Hepatic veno-occlusive disease has been reported.</p>
<p>
		     
	<span class="Italics">Pulmonary</span> — Parenchymal toxicity, including <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, and <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">adult respiratory distress syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>), has been reported rarely following one or more doses of gemcitabine administered to patients with various malignancies. Some patients experienced the onset of pulmonary symptoms up to 2 weeks after the last gemcitabine dose. <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">Respiratory failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> occurred very rarely in some patients despite discontinuation of therapy.</p>
<p>
		     
	<span class="Italics">Renal </span>— <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic Uremic Syndrome</span> (HUS) and/or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> have been reported following one or more doses of gemcitabine. <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or requiring dialysis, despite discontinuation of therapy, has been rarely reported. The majority of the cases of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were due to HUS.</p>
<p>
		     
	<span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>, and Procedural Complications </span>— Radiation recall reactions have been reported <span class="Italics">[see </span><span class="Italics"><a href="#_5_WARNINGS_AND">Warnings and Precautions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_5_8_Radiation_Therapy">5.8</a></span><span class="Italics">)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="_7_DRUG_INTERACTIONS"></a><a name="section-7"></a><p></p>
<h1>
<span class="Bold">7</span><span class="Bold">
		     
	DRUG INTERACTIONS</span>
</h1>
<p class="First">
		     
	No specific drug interaction studies have been conducted. Information is available on the pharmacodynamics and pharmacokinetics of gemcitabine in combination with cisplatin, paclitaxel, or carboplatin <span class="Italics">[see </span><span class="Italics"><a href="#_12_CLINICAL_PHARMACOLOGY">Clinical Pharmacology</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_12_2_Pharmacodynamics">12.2</a></span><span class="Italics"> and </span><span class="Italics"><a href="#_12_3_Pharmacokinetics">12.3</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="_8_USE_IN"></a><a name="section-8"></a><p></p>
<h1>
<span class="Bold">8</span><span class="Bold">
		     
	USE IN SPECIFIC POPULATIONS</span>
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="_8_1_Pregnancy"></a><a name="section-8.1"></a><p></p>
<h2>
<span class="Bold">8.1</span><span class="Bold">
		     
	Pregnancy</span>
</h2>
<p class="First">
		     
	Pregnancy Category D. See ‘<a href="#_5_WARNINGS_AND">Warnings and Precautions</a>’ section.</p>
<p>
		     
	Gemcitabine can cause fetal harm when administered to a pregnant woman. Based on its mechanism of action, gemcitabine is expected to result in adverse reproductive effects. There are no adequate and well-controlled studies of gemcitabine in pregnant women. Gemcitabine is embryotoxic causing <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> (<span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, incomplete ossification) at doses of 1.5 mg/kg/day in mice (about 1/200 the recommended human dose on a mg/m<span class="Sup">2</span> basis). Gemcitabine is fetotoxic causing <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> (fused pulmonary artery, absence of gall bladder) at doses of 0.1 mg/kg/day in rabbits (about 1/600 the recommended human dose on a mg/m<span class="Sup">2</span> basis). Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span>. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus <span class="Italics">[see </span><span class="Italics"><a href="#_5_WARNINGS_AND">Warnings and Precautions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_5_6_Pregnancy">5.6</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="_8_3_Nursing_Mothers"></a><a name="section-8.2"></a><p></p>
<h2>
<span class="Bold">8.3</span><span class="Bold">
		     
	Nursing Mothers</span>
</h2>
<p class="First">
		     
	It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from gemcitabine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>
<span class="Bold">8.4</span><span class="Bold">
		     
	Pediatric Use</span>
</h2>
<p class="First">
		     
	The safety and effectiveness of gemcitabine in pediatric patients has not been established. Gemcitabine was evaluated in a Phase 1 trial in pediatric patients with refractory <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> and determined that the maximum tolerated dose was 10 mg/m<span class="Sup">2</span>/min for 360 minutes three times weekly followed by a one-week rest period. Gemcitabine was also evaluated in a Phase 2 trial in patients with relapsed <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> (22 patients) and acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (10 patients) using 10 mg/m<span class="Sup">2</span>/min for 360 minutes three times weekly followed by a one-week rest period. Toxicities observed included bone marrow suppression, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, elevation of serum transaminases, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>/<span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, which were similar to those reported in adults. No meaningful clinical activity was observed in this Phase 2 trial.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>
<span class="Bold">8.5</span><span class="Bold">
		     
	Geriatric Use</span>
</h2>
<p class="First">
		     
	Gemcitabine clearance is affected by age <span class="Italics">[see </span><span class="Italics"><a href="#_12_CLINICAL_PHARMACOLOGY">Clinical Pharmacology</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_12_3_Pharmacokinetics">12.3</a></span><span class="Italics">)]</span>. There is no evidence, however, that unusual dose adjustments <span class="Italics">[see </span><span class="Italics"><a href="#_2_DOSAGE_AND">Dosage and Administration</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_2_1_Ovarian_Cancer">2.1</a></span><span class="Italics">, </span><span class="Italics"><a href="#_2_2_Breast_Cancer">2.2</a></span><span class="Italics">, </span><span class="Italics"><a href="#_2_3_Non_Small_Cell">2.3</a></span><span class="Italics">, and </span><span class="Italics"><a href="#_2_4_Pancreatic_Cancer">2.4</a></span><span class="Italics">)] </span>are necessary in patients over 65, and in general, adverse reaction rates in the single-agent safety database of 979 patients were similar in patients above and below 65. Grade 3/4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> was more common in the elderly. In the randomized clinical trial of gemcitabine in combination with carboplatin for recurrent ovarian cancer <span class="Italics">[see </span><span class="Italics"><a href="#_14_CLINICAL_STUDIES">Clinical Studies</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_14_1_Ovarian_Cancer">14.1</a></span><span class="Italics">)]</span>, 125 women treated with gemcitabine plus carboplatin were &lt;65 years and 50 were ≥65 years. Similar effectiveness was observed between older and younger women. There was significantly higher Grade 3/4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> in women 65 years of age or older. Overall, there were no other substantial differences in toxicity profile of gemcitabine plus carboplatin based on age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_8_6_Renal"></a><a name="section-8.5"></a><p></p>
<h2>
<span class="Bold">8.6</span><span class="Bold">
		     
	Renal</span>
</h2>
<p class="First">
		     
	<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic Uremic Syndrome</span> (HUS) and/or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> have been reported following one or more doses of gemcitabine. <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or requiring dialysis, despite discontinuation of therapy, has been reported. The majority of the cases of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were due to HUS <span class="Italics">[see </span><span class="Italics"><a href="#_6_ADVERSE_REACTIONS">Adverse Reactions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_6_1_Clinical_Trials">6.1</a></span><span class="Italics"> and </span><span class="Italics"><a href="#_6_2_Post_Marketing_Experience">6.2</a></span><span class="Italics">)]</span>.</p>
<p>
		     
	Gemcitabine should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> as there is insufficient information from clinical studies to allow clear dose recommendation for these patient populations <span class="Italics">[see </span><span class="Italics"><a href="#_5_WARNINGS_AND">Warnings and Precautions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_5_4_Renal">5.4</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_8_7_Hepatic"></a><a name="section-8.6"></a><p></p>
<h2>
<span class="Bold">8.7</span><span class="Bold">
		     
	Hepatic</span>
</h2>
<p class="First">
		     
	Serious hepatotoxicity, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients receiving gemcitabine alone or in combination with other potentially hepatotoxic drugs <span class="Italics">[see </span><span class="Italics"><a href="#_6_ADVERSE_REACTIONS">Adverse Reactions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_6_1_Clinical_Trials">6.1</a></span><span class="Italics"> and </span><span class="Italics"><a href="#_6_2_Post_Marketing_Experience">6.2</a></span><span class="Italics">)</span><span class="Italics">]</span>.</p>
<p>
		     
	Gemcitabine should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> as there is insufficient information from clinical studies to allow clear dose recommendation for these patient populations. Administration of gemcitabine in patients with concurrent liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> or a preexisting medical history of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>, or <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">liver cirrhosis</span> may lead to exacerbation of the underlying <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> <span class="Italics">[see </span><span class="Italics"><a href="#_5_WARNINGS_AND">Warnings and Precautions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_5_5_Hepatic">5.5</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7"></a><p></p>
<h2>
<span class="Bold">8.8</span><span class="Bold">
		     
	Gender</span>
</h2>
<p class="First">
		     
	Gemcitabine clearance is affected by gender <span class="Italics">[see </span><span class="Italics"><a href="#_12_CLINICAL_PHARMACOLOGY">Clinical Pharmacology</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_12_3_Pharmacokinetics">12.3</a></span><span class="Italics">)]</span>. In the single-agent safety database (N=979 patients), however, there is no evidence that unusual dose adjustments <span class="Italics">[see </span><span class="Italics"><a href="#_2_DOSAGE_AND">Dosage and Administration</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_2_DOSAGE_AND">2</a></span><span class="Italics">)] </span>are necessary in women. In general, in single-agent studies of gemcitabine, adverse reaction rates were similar in men and women, but women, especially older women, were more likely not to proceed to a subsequent cycle and to experience Grade 3/4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. There was a greater tendency in women, especially older women, not to proceed to the next cycle.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>
<span class="Bold">10</span><span class="Bold">
		     
	OVERDOSAGE</span>
</h1>
<p class="First">
		     
	There is no known antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of gemcitabine for injection. <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, and severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> were the principal toxicities seen when a single dose as high as 5700 mg/m<span class="Sup">2</span> was administered by intravenous infusion over 30 minutes every 2 weeks to several patients in a Phase 1 study. In the event of suspected <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the patient should be monitored with appropriate blood counts and should receive supportive therapy, as necessary.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>
<span class="Bold">11</span><span class="Bold">
		     
	DESCRIPTION</span>
</h1>
<p class="First">
		     
	Gemcitabine for injection, USP is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl is 2´-deoxy-2´,2´-difluorocytidine monohydrochloride (β-isomer).</p>
<p>
		     
	The structural formula is as follows:</p>
<p>
		     
	<img alt="The structural formula for Gemcitabine Hydrochloride." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd&amp;name=gemcitabine-for-injection-usp-01.jpg"></p>
<p>
		     
	The molecular formula for gemcitabine HCl is C<span class="Sub">9</span>H<span class="Sub">11</span>F<span class="Sub">2</span>N<span class="Sub">3</span>O<span class="Sub">4</span> • HCl. It has a molecular weight of 299.66.</p>
<p>
		     
	Gemcitabine HCl is a white to off-white solid. It is soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and polar organic solvents.</p>
<p>
		     
	The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine for injection, USP contain either 200 mg or 1 g of gemcitabine HCl (expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="_12_CLINICAL_PHARMACOLOGY"></a><a name="section-11"></a><p></p>
<h1>
<span class="Bold">12</span><span class="Bold">
		     
	CLINICAL PHARMACOLOGY</span>
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>
<span class="Bold">12.1</span><span class="Bold">
		     
	Mechanism of Action</span>
</h2>
<p class="First">
		     
	Gemcitabine exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and also blocking the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized intracellularly by nucleoside kinases to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effect of gemcitabine is attributed to a combination of two actions of the diphosphate and the triphosphate nucleosides, which leads to inhibition of DNA synthesis. First, gemcitabine diphosphate inhibits ribonucleotide reductase, which is responsible for catalyzing the reactions that generate the deoxynucleoside triphosphates for DNA synthesis. Inhibition of this enzyme by the diphosphate nucleoside causes a reduction in the concentrations of deoxynucleotides, including dCTP. Second, gemcitabine triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP (by the action of the diphosphate) enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabine nucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands. After this addition, there is inhibition of further DNA synthesis. DNA polymerase epsilon is unable to remove the gemcitabine nucleotide and repair the growing DNA strands (masked chain termination). In CEM T lymphoblastoid cells, gemcitabine induces internucleosomal DNA fragmentation, one of the characteristics of programmed <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span>.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="_12_2_Pharmacodynamics"></a><a name="section-11.2"></a><p></p>
<h2>
<span class="Bold">12.2</span><span class="Bold">
		     
	Pharmacodynamics</span>
</h2>
<p class="First">
		     
	Gemcitabine demonstrated dose-dependent synergistic activity with cisplatin <span class="Italics">in vitro</span>. No effect of cisplatin on gemcitabine triphosphate accumulation or DNA double-strand breaks was observed. <span class="Italics">In vivo</span>, gemcitabine showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. Gemcitabine was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to gemcitabine 4 hours before cisplatin produced the greatest interaction.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="_12_3_Pharmacokinetics"></a><a name="section-11.3"></a><p></p>
<h2>
<span class="Bold">12.3</span><span class="Bold">
		     
	Pharmacokinetics</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<h3><span class="Italics">Absorption and Distribution</span></h3>
<p class="First">
		     
	The pharmacokinetics of gemcitabine were examined in 353 patients, with various <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>. Pharmacokinetic parameters were derived using data from patients treated for varying durations of therapy given weekly with periodic rest weeks and using both short infusions (&lt;70 minutes) and long infusions (70 to 285 minutes). The total gemcitabine dose varied from 500 to 3600 mg/m<span class="Sup">2</span>.</p>
<p>
		     
	The volume of distribution was increased with infusion length. Volume of distribution of gemcitabine was 50 L/m<span class="Sup">2</span> following infusions lasting &lt;70 minutes. For long infusions, the volume of distribution rose to 370 L/m<span class="Sup">2</span>.</p>
<p>
		     
	Gemcitabine pharmacokinetics are linear and are described by a 2-compartment model. Population pharmacokinetic analyses of combined single and multiple dose studies showed that the volume of distribution of gemcitabine was significantly influenced by duration of infusion and gender. Gemcitabine plasma protein binding is negligible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<h3><span class="Italics">Metabolism</span></h3>
<p class="First">
		     
	Gemcitabine disposition was studied in 5 patients who received a single 1000 mg/m<span class="Sup">2</span>/30 minute infusion of radiolabeled drug. Within one (1) week, 92% to 98% of the dose was recovered, almost entirely in the urine. Gemcitabine (&lt;10%) and the inactive uracil metabolite, 2´-deoxy-2´,2´-difluorouridine (dFdU), accounted for 99% of the excreted dose. The metabolite dFdU is also found in plasma.</p>
<p>
		     
	The active metabolite, gemcitabine triphosphate, can be extracted from peripheral blood mononuclear cells. The half-life of the terminal phase for gemcitabine triphosphate from mononuclear cells ranges from 1.7 to 19.4 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<h3><span class="Italics">Excretion</span></h3>
<p class="First">
		     
	Clearance of gemcitabine was affected by age and gender. The lower clearance in women and the elderly results in higher concentrations of gemcitabine for any given dose. Differences in either clearance or volume of distribution based on patient characteristics or the duration of infusion result in changes in half-life and plasma concentrations. Table 9 shows plasma clearance and half-life of gemcitabine following short infusions for typical patients by age and gender.</p>
<table>
<caption><span>Table 9: Gemcitabine Clearance and Half-Life for the “Typical? Patient</span></caption>
<col width="144">
<col width="144">
<col width="144">
<col width="144">
<col width="145">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center">Age</td>
<td class="Lrule Rrule Toprule" align="center">Clearance<br>Men<br>(L/hr/m<span class="Sup">2</span>)</td>
<td class="Lrule Rrule Toprule" align="center">Clearance<br>Women<br>(L/hr/m<span class="Sup">2</span>)</td>
<td class="Lrule Rrule Toprule" align="center">Half-Life<span class="Sup">a</span><br>Men<br>(min)</td>
<td class="Lrule Rrule Toprule" align="center">Half-Life<span class="Sup">a</span><br>Women<br>(min)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">29</td>
<td class="Lrule Rrule Toprule" align="center">92.2</td>
<td class="Lrule Rrule Toprule" align="center">69.4</td>
<td class="Lrule Rrule Toprule" align="center">42</td>
<td class="Lrule Rrule Toprule" align="center">49</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">45</td>
<td class="Lrule Rrule Toprule" align="center">75.7</td>
<td class="Lrule Rrule Toprule" align="center">57.0</td>
<td class="Lrule Rrule Toprule" align="center">48</td>
<td class="Lrule Rrule Toprule" align="center">57</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">65</td>
<td class="Lrule Rrule Toprule" align="center">55.1</td>
<td class="Lrule Rrule Toprule" align="center">41.5</td>
<td class="Lrule Rrule Toprule" align="center">61</td>
<td class="Lrule Rrule Toprule" align="center">73</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="center">79</td>
<td class="Lrule Rrule Toprule" align="center">40.7</td>
<td class="Lrule Rrule Toprule" align="center">30.7</td>
<td class="Lrule Rrule Toprule" align="center">79</td>
<td class="Lrule Rrule Toprule" align="center">94</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Half-life for patients receiving a short infusion (&lt;70 min).</p>
<p>
		     
	Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-11.3.4"></a><p></p>
<h3><span class="Italics">Drug Interactions</span></h3>
<p class="First">
		     
	When gemcitabine (1250 mg/m<span class="Sup">2</span> on Days 1 and 8) and cisplatin (75 mg/m<span class="Sup">2</span> on Day 1) were administered in NSCLC patients, the clearance of gemcitabine on Day 1 was 128 L/hr/m<span class="Sup">2</span> and on Day 8 was 107 L/hr/m<span class="Sup">2</span>. The clearance of cisplatin in the same study was reported to be 3.94 mL/min/m<span class="Sup">2</span> with a corresponding half-life of 134 hours <span class="Italics">[see </span><span class="Italics"><a href="#_7_DRUG_INTERACTIONS">Drug Interactions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_7_DRUG_INTERACTIONS">7</a></span><span class="Italics">)]</span>. Analysis of data from metastatic breast cancer patients shows that, on average, gemcitabine has little or no effect on the pharmacokinetics (clearance and half-life) of paclitaxel and paclitaxel has little or no effect on the pharmacokinetics of gemcitabine. Data from NSCLC patients demonstrate that gemcitabine and carboplatin given in combination does not alter the pharmacokinetics of gemcitabine or carboplatin compared to administration of either single-agent. However, due to wide confidence intervals and small sample size, interpatient variability may be observed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>
<span class="Bold">13</span><span class="Bold">
		     
	NONCLINICAL TOXICOLOGY</span>
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">13.1</span><span class="Bold">
		     
	Carcinogenesis, Mutagenesis, Impairment of Fertility</span>
</h2>
<p class="First">
		     
	Long-term animal studies to evaluate the carcinogenic potential of gemcitabine have not been conducted. Gemcitabine induced forward mutations <span class="Italics">in vitro</span> in a mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (L5178Y) assay and was clastogenic in an <span class="Italics">in vivo</span> mouse micronucleus assay. Gemcitabine was negative when tested using the Ames, <span class="Italics">in vivo</span> sister chromatid exchange, and <span class="Italics">in vitro</span> chromosomal aberration assays, and did not cause unscheduled DNA synthesis <span class="Italics">in vitro</span>. Gemcitabine IP doses of 0.5 mg/kg/day (about 1/700 the human dose on a mg/m<span class="Sup">2</span> basis) in male mice had an effect on fertility with moderate to severe hypospermatogenesis, decreased fertility, and decreased implantations. In female mice, fertility was not affected but maternal toxicities were observed at 1.5 mg/kg/day administered intravenously (about 1/200 the human dose on a mg/m<span class="Sup">2</span> basis) and fetotoxicity or embryolethality was observed at 0.25 mg/kg/day administered intravenously (about 1/1300 the human dose on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="_14_CLINICAL_STUDIES"></a><a name="section-13"></a><p></p>
<h1>
<span class="Bold">14</span><span class="Bold">
		     
	CLINICAL STUDIES</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_14_1_Ovarian_Cancer"></a><a name="section-13.1"></a><p></p>
<h2>
<span class="Bold">14.1</span><span class="Bold">
		     
	Ovarian Cancer</span>
</h2>
<p class="First">
		     
	Gemcitabine was studied in a randomized Phase 3 study of 356 patients with advanced ovarian cancer that had relapsed at least 6 months after first-line platinum-based therapy. Patients were randomized to receive either gemcitabine 1000 mg/m<span class="Sup">2</span> on Days 1 and 8 of a 21-day cycle and carboplatin AUC 4 administered after gemcitabine on Day 1 of each cycle or single-agent carboplatin AUC 5 administered on Day 1 of each 21-day cycle as the control arm. The primary endpoint of this study was progression free survival (PFS).</p>
<p>
		     
	Patient characteristics are shown in Table 10. The addition of gemcitabine to carboplatin resulted in statistically significant improvement in PFS and overall response rate as shown in Table 11 and Figure 1. Approximately 75% of patients in each arm received poststudy chemotherapy. Only 13 of 120 patients with documented poststudy chemotherapy regimen in the carboplatin arm received gemcitabine after progression. There was not a significant difference in overall survival between arms.</p>
<table>
<caption><span>Table 10: Gemcitabine Plus Carboplatin Versus Carboplatin in Ovarian Cancer - Baseline Demographics and Clinical Characteristics</span></caption>
<col width="353">
<col width="192">
<col width="176">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center">Gemcitabine/Carboplatin</td>
<td class="Lrule Rrule Toprule" align="center">Carboplatin</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Number of randomized patients</td>
<td class="Lrule Rrule Toprule" align="center">178</td>
<td class="Lrule Rrule Toprule" align="center">178</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Median age, years</td>
<td class="Lrule Rrule Toprule" align="center">59</td>
<td class="Lrule Rrule Toprule" align="center">58</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Range</td>
<td class="Lrule Rrule" align="center">36 to 78</td>
<td class="Lrule Rrule" align="center">21 to 81</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Baseline ECOG performance status 0 to 1<span class="Sup">a</span>
</td>
<td class="Lrule Rrule Toprule" align="center">94%</td>
<td class="Lrule Rrule Toprule" align="center">95%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Disease Status</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Evaluable</td>
<td class="Lrule Rrule" align="center">7.9%</td>
<td class="Lrule Rrule" align="center">2.8%</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Bidimensionally measurable</td>
<td class="Lrule Rrule" align="center">91.6%</td>
<td class="Lrule Rrule" align="center">95.5%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Platinum-free interval<span class="Sup">b</span> 6 to 12 months</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">39.9%</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">39.9%</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	&gt;12 months</td>
<td class="Lrule Rrule" align="center">59.0%</td>
<td class="Lrule Rrule" align="center">59.6%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">First-line therapy</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Platinum-taxane combination</td>
<td class="Lrule Rrule" align="center">70.2%</td>
<td class="Lrule Rrule" align="center">71.3%</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Platinum-non-taxane combination</td>
<td class="Lrule Rrule" align="center">28.7%</td>
<td class="Lrule Rrule" align="center">27.5%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule">
		     
	Platinum monotherapy</td>
<td class="Lrule Rrule" align="center">1.1%</td>
<td class="Lrule Rrule" align="center">1.1%</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Nine patients (5 on the gemcitabine plus carboplatin arm and 4 on the carboplatin arm) did not have baseline Eastern Cooperative Oncology Group (ECOG) performance status recorded.</p>
<p><span class="Sup">b</span> Three patients (2 on the gemcitabine plus carboplatin arm and 1 on the carboplatin arm) had a platinum-free interval of less than 6 months.</p>
<table>
<caption><span>Table 11: Gemcitabine Plus Carboplatin Versus Carboplatin in Ovarian Cancer - Results of Efficacy Analysis</span></caption>
<col width="366">
<col width="176">
<col width="131">
<col width="84">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center">Gemcitabine/Carboplatin<br>(n=178)</td>
<td class="Lrule Rrule Toprule" align="center">Carboplatin<br>(N=178)</td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">PFS</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Median (95%, C.I.) months</td>
<td class="Lrule Rrule" align="center">8.6 (8.0, 9.7)</td>
<td class="Lrule Rrule" align="center">5.8 (5.2, 7.1)</td>
<td class="Lrule Rrule" align="center">p=0.038<span class="Sup">d</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Hazard Ratio (95%, C.I.)</td>
<td class="Lrule Toprule" align="center" colspan="2">0.72 (0.57, 0.90)</td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Overall Survival</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Median (95%, C.I.) months</td>
<td class="Lrule Rrule" align="center">18.0 (16.2, 20.3)</td>
<td class="Lrule Rrule" align="center">17.3 (15.2, 19.3)</td>
<td class="Lrule Rrule">p=0.8977<span class="Sup">d</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Hazard Ratio (95%, C.I.)</td>
<td class="Lrule Toprule" align="center" colspan="2">0.98 (0.78, 1.24)</td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Adjusted<span class="Sup">a</span> Hazard Ratio (95%, C.I.)</td>
<td class="Lrule Toprule" align="center" colspan="2">0.86 (0.67, 1.10)</td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Investigator Reviewed</td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Overall Response Rate</td>
<td class="Lrule Rrule" align="center">47.2%</td>
<td class="Lrule Rrule" align="center">30.9%</td>
<td class="Lrule Rrule" align="center">p=0.0016<span class="Sup">e</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	CR</td>
<td class="Lrule Rrule" align="center">14.6%</td>
<td class="Lrule Rrule" align="center">6.2%</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	PR+PRNM<span class="Sup">b</span>
</td>
<td class="Lrule Rrule" align="center">32.6%</td>
<td class="Lrule Rrule" align="center">24.7%</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Independently Reviewed</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Overall Response Rate <span class="Sup">c,f</span>
</td>
<td class="Lrule Rrule" align="center">46.3%</td>
<td class="Lrule Rrule" align="center">35.6%</td>
<td class="Lrule Rrule" align="center">p=0.11<span class="Sup">e</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	CR</td>
<td class="Lrule Rrule" align="center">9.1%</td>
<td class="Lrule Rrule" align="center">4.0%</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule">
		     
	PR+PRNM</td>
<td class="Lrule Rrule" align="center">37.2%</td>
<td class="Lrule Rrule" align="center">31.7%</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Treatment adjusted for performance status, tumor area, and platinum-free interval.</p>
<p><span class="Sup">b</span> Partial response non-measurable disease</p>
<p><span class="Sup">c</span> Independent reviewers could not evaluate disease demonstrated by sonography or physical exam.</p>
<p><span class="Sup">d</span> Log Rank, unadjusted</p>
<p><span class="Sup">e</span> Chi Square</p>
<p><span class="Sup">f</span> Independently reviewed cohort - Gemcitabine/Carboplatin N=121, Carboplatin N=101</p>
<p><img alt="Figure 1: Kaplan-Meier Curve of Progression Free Survival in Gemcitabine Plus Carboplatin Versus Carboplatin in Ovarian Cancer (N=356)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd&amp;name=gemcitabine-for-injection-usp-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>
<span class="Bold">14.2</span><span class="Bold">
		     
	Breast Cancer</span>
</h2>
<p class="First">
		     
	Data from a multi-national, randomized Phase 3 study (529 patients) support the use of gemcitabine in combination with paclitaxel for treatment of breast cancer patients who have received prior adjuvant/neoadjuvant anthracycline chemotherapy unless clinically contraindicated. Gemcitabine 1250 mg/m<span class="Sup">2</span> was administered on Days 1 and 8 of a 21-day cycle with paclitaxel 175 mg/m<span class="Sup">2</span> administered prior to gemcitabine on Day 1 of each cycle. Single-agent paclitaxel 175 mg/m<span class="Sup">2</span> was administered on Day 1 of each 21-day cycle as the control arm.</p>
<p>
		     
	The addition of gemcitabine to paclitaxel resulted in statistically significant improvement in time to documented disease progression and overall response rate compared to monotherapy with paclitaxel as shown in Table 12 and Figure 2. Final survival analysis results at 440 events were Hazard Ratio of 0.86 (95%, CI: 0.71 to 1.04) for the ITT population, as shown in Table 12.</p>
<table>
<caption><span>Table 12: Gemcitabine Plus Paclitaxel Versus Paclitaxel in Breast Cancer</span></caption>
<col width="366">
<col width="174">
<col width="150">
<col width="84">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center">Gemcitabine/Paclitaxel</td>
<td class="Lrule Rrule Toprule" align="center">Paclitaxel</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Number of Patients</td>
<td class="Lrule Rrule Toprule" align="center">267</td>
<td class="Lrule Rrule Toprule" align="center">262</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
		     
	Median age, years</td>
<td class="Lrule Rrule Toprule" align="center">53</td>
<td class="Lrule Rrule Toprule" align="center">52</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Range</td>
<td class="Lrule Rrule" align="center">26 to 83</td>
<td class="Lrule Rrule" align="center">26 to 75</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span></td>
<td class="Lrule Rrule Toprule" align="center">97.0%</td>
<td class="Lrule Rrule Toprule" align="center">96.9%</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Baseline KPS<span class="Sup">a</span> ≥90</td>
<td class="Lrule Rrule Toprule" align="center">70.4%</td>
<td class="Lrule Rrule Toprule" align="center">74.4%</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Number of tumor sites</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	1 to 2</td>
<td class="Lrule Rrule" align="center">56.6%</td>
<td class="Lrule Rrule" align="center">58.8%</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	≥3</td>
<td class="Lrule Rrule" align="center">43.4%</td>
<td class="Lrule Rrule" align="center">41.2%</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Visceral disease</td>
<td class="Lrule Rrule Toprule" align="center">73.4%</td>
<td class="Lrule Rrule Toprule" align="center">72.9%</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Prior anthracycline</td>
<td class="Lrule Rrule Toprule" align="center">96.6%</td>
<td class="Lrule Rrule Toprule" align="center">95.8%</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Overall Survival<span class="Sup">b</span>
</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
		     
	Median (95%, C.I.)</td>
<td class="Lrule Rrule Toprule" align="center">18.6 (16.5., 20.7)</td>
<td class="Lrule Rrule Toprule" align="center">15.8 (14.1, 17.3)</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
		     
	Hazard Ratio (95%, C.I.)</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">0.86 (0.71, 1.04)</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Time to Documented Disease Progression<span class="Sup">c</span>
</td>
<td class="Lrule Rrule Toprule" align="center">
<br>5.2 (4.2, 5.6)</td>
<td class="Lrule Rrule Toprule" align="center">
<br>2.9 (2.6, 3.7)</td>
<td class="Lrule Rrule Toprule" align="center">p&lt;0.0001</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Median (95%, C.I.), months</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Hazard Ratio (95%, C.I.)</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">0.650 (0.524, 0.805)</td>
<td class="Lrule Rrule Toprule" align="center">p&lt;0.0001</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule">
		     
	Overall Response Rate<span class="Sup">c</span> (95%, C.I.)</td>
<td class="Lrule Rrule Toprule" align="center">40.8% (34.9, 46.7)</td>
<td class="Lrule Rrule Toprule" align="center">22.1% (17.1, 27.2)</td>
<td class="Lrule Rrule Toprule" align="center">p&lt;0.0001</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Karnofsky Performance Status.</p>
<p><span class="Sup">b</span> Based on the ITT population</p>
<p><span class="Sup">c</span> These represent reconciliation of investigator and Independent Review Committee assessments according to a predefined algorithm.</p>
<p><img alt="Figure 2: Kaplan-Meier Curve of Time to Documented Disease Progression in Gemcitabine Plus Paclitaxel Versus Paclitaxel Breast Cancer Study (N=529)." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd&amp;name=gemcitabine-for-injection-usp-03.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_14_3_Non_Small_Cell"></a><a name="section-13.3"></a><p></p>
<h2>
<span class="Bold">14.3</span><span class="Bold">
		     
	Non-Small Cell Lung Cancer (NSCLC)</span>
</h2>
<p class="First">
		     
	Data from 2 randomized clinical studies (657 patients) support the use of gemcitabine in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC.</p>
<p>
		     
	<span class="Underline">Gemcitabine plus cisplatin versus cisplatin:</span> This study was conducted in Europe, the US, and Canada in 522 patients with inoperable Stage IIIA, IIIB, or IV NSCLC who had not received prior chemotherapy. Gemcitabine 1000 mg/m<span class="Sup">2</span> was administered on Days 1, 8, and 15 of a 28-day cycle with cisplatin 100 mg/m<span class="Sup">2</span> administered on Day 1 of each cycle. Single-agent cisplatin 100 mg/m<span class="Sup">2</span> was administered on Day 1 of each 28-day cycle. The primary endpoint was survival. Patient demographics are shown in Table 13. An imbalance with regard to histology was observed with 48% of patients on the cisplatin arm and 37% of patients on the gemcitabine plus cisplatin arm having adenocarcinoma.</p>
<p>
		     
	The Kaplan-Meier survival curve is shown in Figure 3. Median survival time on the gemcitabine plus cisplatin arm was 9.0 months compared to 7.6 months on the single-agent cisplatin arm (Log rank p=0.008, two-sided). Median time to disease progression was 5.2 months on the gemcitabine plus cisplatin arm compared to 3.7 months on the cisplatin arm (Log rank p=0.009, two-sided). The objective response rate on the gemcitabine plus cisplatin arm was 26% compared to 10% with cisplatin (Fisher’s Exact p&lt;0.0001, two-sided). No difference between treatment arms with regard to duration of response was observed.</p>
<p>
		     
	<span class="Underline">Gemcitabine plus cisplatin versus etoposide plus cisplatin:</span> A second, multicenter, study in Stage IIIB or IV NSCLC randomized 135 patients to gemcitabine 1250 mg/m<span class="Sup">2</span> on Days 1 and 8, and cisplatin 100 mg/m<span class="Sup">2</span> on Day 1 of a 21-day cycle or to intravenous etoposide 100 mg/m<span class="Sup">2</span> on Days 1, 2, and 3 and cisplatin 100 mg/m<span class="Sup">2</span> on Day 1 of a 21-day cycle (Table 13).</p>
<p>
		     
	There was no significant difference in survival between the two treatment arms (Log rank p=0.18, two-sided). The median survival was 8.7 months for the gemcitabine plus cisplatin arm versus 7.0 months for the etoposide plus cisplatin arm. Median time to disease progression for the gemcitabine plus cisplatin arm was 5.0 months compared to 4.1 months on the etoposide plus cisplatin arm (Log rank p=0.015, two-sided). The objective response rate for the gemcitabine plus cisplatin arm was 33% compared to 14% on the etoposide plus cisplatin arm (Fisher’s Exact p=0.01, two-sided).</p>
<p>
		     
	</p>
<p><img alt="Figure 3: Kaplan-Meier Survival Curve in Gemcitabine Plus Cisplatin Versus Cisplatin NSCLC Study (N=522)." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd&amp;name=gemcitabine-for-injection-usp-04.jpg"></p>
<table>
<caption><span>Table 13: Randomized Trials of Combination Therapy With Gemcitabine Plus Cisplatin in NSCLC</span></caption>
<col width="210">
<col width="108">
<col width="90">
<col width="90">
<col width="108">
<col width="126">
<col width="78">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule">Trial</td>
<td class="Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">28-day Schedule</span><span class="Bold"><span class="Sup">a</span></span>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">21-day Schedule</span><span class="Bold"><span class="Sup">b</span></span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Treatment Arm</td>
<td class="Lrule Rrule Toprule" align="center">Gemcitabine/<br>Cisplatin</td>
<td class="Lrule Rrule Toprule" align="center">Cisplatin</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">Gemcitabine/<br>Cisplatin</td>
<td class="Lrule Rrule Toprule" align="center">Cisplatin/<br>Etoposide</td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Number of patients</td>
<td class="Lrule Rrule Toprule" align="center">260</td>
<td class="Lrule Rrule Toprule" align="center">262</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">69</td>
<td class="Lrule Rrule Toprule" align="center">66</td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Male</td>
<td class="Lrule Rrule" align="center">182</td>
<td class="Lrule Rrule" align="center">186</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">64</td>
<td class="Lrule Rrule" align="center">61</td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Female</td>
<td class="Lrule Rrule" align="center">78</td>
<td class="Lrule Rrule" align="center">76</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Median age, years</td>
<td class="Lrule Rrule Toprule" align="center">62</td>
<td class="Lrule Rrule Toprule" align="center">63</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">58</td>
<td class="Lrule Rrule Toprule" align="center">60</td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Range</td>
<td class="Lrule Rrule" align="center">36 to 88</td>
<td class="Lrule Rrule" align="center">35 to 79</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">33 to 76</td>
<td class="Lrule Rrule" align="center">35 to 75</td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Stage IIIA</td>
<td class="Lrule Rrule Toprule" align="center">7%</td>
<td class="Lrule Rrule Toprule" align="center">7%</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">N/A<span class="Sup">c</span>
</td>
<td class="Lrule Rrule Toprule" align="center">N/A<span class="Sup">c</span>
</td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule">Stage IIIB</td>
<td class="Lrule Rrule" align="center">26%</td>
<td class="Lrule Rrule" align="center">23%</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">48%</td>
<td class="Lrule Rrule" align="center">52%</td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule">Stage IV</td>
<td class="Lrule Rrule" align="center">67%</td>
<td class="Lrule Rrule" align="center">70%</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">52%</td>
<td class="Lrule Rrule" align="center">49%</td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Baseline KPS<span class="Sup">d</span> 70 to 80</td>
<td class="Lrule Rrule Toprule" align="center">41%</td>
<td class="Lrule Rrule Toprule" align="center">44%</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">45%</td>
<td class="Lrule Rrule Toprule" align="center">52%</td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule">Baseline KPS<span class="Sup">d</span> 90 to 100</td>
<td class="Lrule Rrule" align="center">57%</td>
<td class="Lrule Rrule" align="center">55%</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">55%</td>
<td class="Lrule Rrule" align="center">49%</td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Toprule"><br></td>
<td class="Toprule"><br></td>
<td class="Toprule"><br></td>
<td class="Toprule"><br></td>
<td class="Toprule"><br></td>
<td class="Toprule"><br></td>
<td class="Rrule Toprule"><br></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Survival</td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center">p=0.008</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">p=0.18</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Median, months</td>
<td class="Lrule Rrule" align="center">9.0</td>
<td class="Lrule Rrule" align="center">7.6</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">8.7</td>
<td class="Lrule Rrule" align="center">7.0</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	(95%, C.I.) months</td>
<td class="Lrule Rrule" align="center">8.2, 11.0</td>
<td class="Lrule Rrule" align="center">6.6, 8.8</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">7.8, 10.1</td>
<td class="Lrule Rrule" align="center">6.0, 9.7</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Time to Disease Progression</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">p=0.009</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">p=0.015</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Median, months</td>
<td class="Lrule Rrule" align="center">5.2</td>
<td class="Lrule Rrule" align="center">3.7</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">5.0</td>
<td class="Lrule Rrule" align="center">4.1</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	(95%, C.I.) months</td>
<td class="Lrule Rrule" align="center">4.2, 5.7</td>
<td class="Lrule Rrule" align="center">3.0, 4.3</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">4.2, 6.4</td>
<td class="Lrule Rrule" align="center">2.4, 4.5</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule">Tumor Response</td>
<td class="Lrule Rrule Toprule" align="center">26%</td>
<td class="Lrule Rrule Toprule" align="center">10%</td>
<td class="Lrule Rrule Toprule" align="center">p&lt;0.0001<span class="Sup">e</span>
</td>
<td class="Lrule Rrule Toprule" align="center">33%</td>
<td class="Lrule Rrule Toprule" align="center">14%</td>
<td class="Lrule Rrule Toprule" align="center">p=0.01<span class="Sup">e</span>
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> 28-day schedule — gemcitabine plus cisplatin: gemcitabine 1000 mg/m<span class="Sup">2</span> on Days 1, 8, and 15 and cisplatin 100 mg/m<span class="Sup">2</span> on Day 1 every 28 days; Single-agent cisplatin: cisplatin 100 mg/m<span class="Sup">2</span> on Day 1 every 28 days.</p>
<p><span class="Sup">b</span> 21-day schedule — gemcitabine plus cisplatin: gemcitabine 1250 mg/m<span class="Sup">2</span> on Days 1 and 8 and cisplatin 100 mg/m<span class="Sup">2</span> on Day 1 every 21 days; Etoposide plus Cisplatin: cisplatin 100 mg/m<span class="Sup">2</span> on Day 1 and intravenous etoposide 100 mg/m<span class="Sup">2</span> on Days 1, 2, and 3 every 21 days.</p>
<p><span class="Sup">c</span> N/A Not applicable.</p>
<p><span class="Sup">d</span> Karnofsky Performance Status.</p>
<p><span class="Sup">e</span> p-value for tumor response was calculated using the two-sided Fisher’s Exact test for difference in binomial proportions. All other p-values were calculated using the Log rank test for difference in overall time to an event.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.4"></a><p></p>
<h2>
<span class="Bold">14.4</span><span class="Bold">
		     
	Pancreatic Cancer</span>
</h2>
<p class="First">
		     
	Data from 2 clinical trials evaluated the use of gemcitabine in patients with locally advanced or metastatic pancreatic cancer. The first trial compared gemcitabine to 5-Fluorouracil (5-FU) in patients who had received no prior chemotherapy. A second trial studied the use of gemcitabine in pancreatic cancer patients previously treated with 5-FU or a 5-FU-containing regimen. In both studies, the first cycle of gemcitabine was administered intravenously at a dose of 1000 mg/m<span class="Sup">2</span> over 30 minutes once weekly for up to 7 weeks (or until toxicity necessitated holding a dose) followed by a week of rest from treatment with gemcitabine. Subsequent cycles consisted of injections once weekly for 3 consecutive weeks out of every 4 weeks.</p>
<p>
		     
	The primary efficacy parameter in these studies was “clinical benefit response,? which is a measure of clinical improvement based on analgesic consumption, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity, performance status, and weight change. Definitions for improvement in these variables were formulated prospectively during the design of the 2 trials. A patient was considered a clinical benefit responder if either:</p>
<ol class="LittleRoman">
<li>the patient showed a ≥50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity (Memorial <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Assessment Card) or analgesic consumption, or a 20-point or greater improvement in performance status (Karnofsky Performance Status) for a period of at least 4 consecutive weeks, without showing any sustained worsening in any of the other parameters. Sustained worsening was defined as 4 consecutive weeks with either any increase in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity or analgesic consumption or a 20-point decrease in performance status occurring during the first 12 weeks of therapy.<br>OR:<br>
</li>
<li>the patient was stable on all of the aforementioned parameters, and showed a marked, sustained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation.</li>
</ol>
<p>
		     
	The first study was a multicenter (17 sites in US and Canada), prospective, single-blinded, two-arm, randomized, comparison of gemcitabine and 5-FU in patients with locally advanced or metastatic pancreatic cancer who had received no prior treatment with chemotherapy. 5-FU was administered intravenously at a weekly dose of 600 mg/m<span class="Sup">2</span> for 30 minutes. The results from this randomized trial are shown in Table 14. Patients treated with gemcitabine had statistically significant increases in clinical benefit response, survival, and time to disease progression compared to 5-FU. The Kaplan-Meier curve for survival is shown in Figure 4. No confirmed objective tumor responses were observed with either treatment.</p>
<table>
<caption><span>Table 14: Gemcitabine Versus 5-FU in Pancreatic Cancer</span></caption>
<col width="325">
<col width="156">
<col width="192">
<col width="84">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center">Gemcitabine</td>
<td class="Lrule Rrule Toprule" align="center">5-FU</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Number of patients</td>
<td class="Lrule Rrule Toprule" align="center">63</td>
<td class="Lrule Rrule Toprule" align="center">63</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Male</td>
<td class="Lrule Rrule" align="center">34</td>
<td class="Lrule Rrule" align="center">34</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Female</td>
<td class="Lrule Rrule" align="center">29</td>
<td class="Lrule Rrule" align="center">29</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Median age</td>
<td class="Lrule Rrule Toprule" align="center">62 years</td>
<td class="Lrule Rrule Toprule" align="center">61 years</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Range</td>
<td class="Lrule Rrule" align="center">37 to 79</td>
<td class="Lrule Rrule" align="center">36 to 77</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Stage IV disease</td>
<td class="Lrule Rrule Toprule" align="center">71.4%</td>
<td class="Lrule Rrule Toprule" align="center">76.2%</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Baseline KPS<span class="Sup">a</span> ≤70</td>
<td class="Lrule Rrule Toprule" align="center">69.8%</td>
<td class="Lrule Rrule Toprule" align="center">68.3%</td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Toprule"><br></td>
<td class="Toprule" align="center"><br></td>
<td class="Toprule" align="center"><br></td>
<td class="Rrule Toprule" align="center"><br></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Clinical benefit response</td>
<td class="Lrule Rrule Toprule" align="center">22.2%<br>(N<span class="Sup">c</span>=14)</td>
<td class="Lrule Rrule Toprule" align="center">4.8%<br>(N<span class="Sup">c</span>=3)</td>
<td class="Lrule Rrule Toprule" align="center">p=0.004<span class="Sup">e</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Survival</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">p=0.0009</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Median</td>
<td class="Lrule Rrule" align="center">5.7 months</td>
<td class="Lrule Rrule" align="center">4.2 months</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	6-month probability<span class="Sup">b</span>
</td>
<td class="Lrule Rrule" align="center">(N=30) 46%</td>
<td class="Lrule Rrule" align="center">(N=19) 29%</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	9-month probability<span class="Sup">b</span>
</td>
<td class="Lrule Rrule" align="center">(N=14) 24%</td>
<td class="Lrule Rrule" align="center">(N=4) 5%</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	1-year probability<span class="Sup">b</span>
</td>
<td class="Lrule Rrule" align="center">(N=9) 18%</td>
<td class="Lrule Rrule" align="center">(N=2) 2%</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Range</td>
<td class="Lrule Rrule" align="center">0.2 to 18.6 months</td>
<td class="Lrule Rrule" align="center">0.4 to 15.1+<span class="Sup">d</span> months</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	95% C.I. of the median</td>
<td class="Lrule Rrule" align="center">4.7 to 6.9 months</td>
<td class="Lrule Rrule" align="center">3.1 to 5.1 months</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Time to Disease Progression</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">p=0.0013</td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Median</td>
<td class="Lrule Rrule" align="center">2.1 months</td>
<td class="Lrule Rrule" align="center">0.9 months</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">
		     
	Range</td>
<td class="Lrule Rrule" align="center">0.1+<span class="Sup">d</span> to 9.4 months</td>
<td class="Lrule Rrule" align="center">0.1 to 12.0+<span class="Sup">d</span> months</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule">
		     
	95% C.I. of the median</td>
<td class="Lrule Rrule" align="center">1.9 to 3.4 months</td>
<td class="Lrule Rrule" align="center">0.9 to 1.1 months</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Karnofsky Performance Status.</p>
<p><span class="Sup">b</span> Kaplan-Meier estimates.</p>
<p><span class="Sup">c</span> N=number of patients.</p>
<p><span class="Sup">d</span> No progression at last visit; remains alive.</p>
<p><span class="Sup">e</span> The p-value for clinical benefit response was calculated using the two-sided test for difference in binomial proportions. All other p-values were calculated using the Log rank test for difference in overall time to an event.</p>
<p>
		     
	Clinical benefit response was achieved by 14 patients treated with gemcitabine and 3 patients treated with 5-FU. One patient on the gemcitabine arm showed improvement in all 3 primary parameters (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity, analgesic consumption, and performance status). Eleven patients on the gemcitabine arm and 2 patients on the 5-FU arm showed improvement in analgesic consumption and/or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity with stable performance status. Two patients on the gemcitabine arm showed improvement in analgesic consumption or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity with improvement in performance status. One patient on the 5-FU arm was stable with regard to <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity and analgesic consumption with improvement in performance status. No patient on either arm achieved a clinical benefit response based on <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
<p>
		     
	</p>
<p>
		     
	<img alt="Figure 4: Kaplan-Meier Survival Curve." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd&amp;name=gemcitabine-for-injection-usp-05.jpg"></p>
<p>
		     
	</p>
<p>
		     
	The second trial was a multicenter (17 US and Canadian centers), open-label study of gemcitabine in 63 patients with advanced pancreatic cancer previously treated with 5-FU or a 5-FU-containing regimen. The study showed a clinical benefit response rate of 27% and median survival of 3.9 months.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_14_5_Other_Clinical"></a><a name="section-13.5"></a><p></p>
<h2>
<span class="Bold">14.5</span><span class="Bold">
		     
	Other Clinical Studies</span>
</h2>
<p class="First">
		     
	When gemcitabine was administered more frequently than once weekly or with infusions longer than 60 minutes, increased toxicity was observed. Results of a Phase 1 study of gemcitabine to assess the maximum tolerated dose (MTD) on a daily x 5 schedule showed that patients developed significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and severe flu-like symptoms that were intolerable at doses above 10 mg/m<span class="Sup">2</span>. The incidence and severity of these events were dose-related. Other Phase 1 studies using a twice-weekly schedule reached MTDs of only 65 mg/m<span class="Sup">2</span> (30-minute infusion) and 150 mg/m<span class="Sup">2</span> (5-minute bolus). The dose-limiting toxicities were <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and flu-like symptoms, particularly <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>. In a Phase 1 study to assess the maximum tolerated infusion time, clinically significant toxicity, defined as <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, was seen with weekly doses of 300 mg/m<span class="Sup">2</span> at or above a 270-minute infusion time. The half-life of gemcitabine is influenced by the length of the infusion <span class="Italics">[see </span><span class="Italics"><a href="#_12_CLINICAL_PHARMACOLOGY">Clinical Pharmacology</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_12_3_Pharmacokinetics">12.3</a></span><span class="Italics">)]</span> and the toxicity appears to be increased if gemcitabine is administered more frequently than once weekly or with infusions longer than 60 minutes <span class="Italics">[see </span><span class="Italics"><a href="#_5_WARNINGS_AND">Warnings and Precautions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_5_1_Infusion_Time">5.1</a></span><span class="Italics">)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="_15_REFERENCES"></a><a name="section-14"></a><p></p>
<h1>
<span class="Bold">15</span><span class="Bold">
		     
	REFERENCES</span>
</h1>
<ol class="Arabic">
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.<br>
</li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html<br>
</li>
<li>American Society of Health-System Pharmacists. ASHP Guidelines on Handling Hazardous Drugs: Am J Health-Syst Pharm. 2006;63:1172-1193.<br>
</li>
<li>Polovich, M., White, J. M., &amp; Kelleher, L. O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<h1>
<span class="Bold">16</span><span class="Bold">
		     
	HOW SUPPLIED/STORAGE AND HANDLING</span>
</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15.1"></a><p></p>
<h2>
<span class="Bold">16.1</span><span class="Bold">
		     
	How Supplied</span>
</h2>
<p class="First">
		     
	Gemcitabine for injection, USP, is a lyophilized powder of gemcitabine hydrochloride (expressed as the free base) and is available in sterile single-use vials individually packaged in a carton containing:</p>
<p>
		     
	200 mg white to off-white, lyophilized powder in a sterile single-use vial - NDC 0591-3562-79 </p>
<p>
		     
	1 g white to off-white, lyophilized powder in a sterile single-use vial - NDC 0591-3563-55</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.2"></a><p></p>
<h2>
<span class="Bold">16.2</span><span class="Bold">
		     
	Storage and Handling</span>
</h2>
<p class="First">
		     
	Unopened vials of gemcitabine for injection, USP are stable until the expiration date indicated on the package when stored at controlled room temperature 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] <span class="Italics">[see </span><span class="Italics"><a href="#_2_DOSAGE_AND">Dosage and Administration</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_2_5_Preparation_and">2.5</a></span><span class="Italics"> and </span><span class="Italics"><a href="#_2_6_Preparation_for">2.6</a></span><span class="Italics">)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>
<span class="Bold">17</span><span class="Bold">
		     
	PATIENT COUNSELING INFORMATION</span><span class="Bold"> </span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<h2>
<span class="Bold">17.1</span><span class="Bold">
		     
	Low Blood Cell Counts</span>
</h2>
<p class="First">
		     
	Patients should be adequately informed of the risk of low blood cell counts and instructed to immediately contact their physician should any sign of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develop including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Patients should also contact their physician if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> occur <span class="Italics">[see </span><span class="Italics"><a href="#_5_WARNINGS_AND">Warnings and Precautions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_5_2_Hematology">5.2</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-16.2"></a><p></p>
<h2>
<span class="Bold">17.2</span><span class="Bold">
		     
	Pregnancy</span>
</h2>
<p class="First">
		     
	There are no adequate and well-controlled studies of gemcitabine for injection in pregnant women. Based on animal studies gemcitabine for injection can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the risks to the fetus need to be discussed with their physician <span class="Italics">[see </span><span class="Italics"><a href="#_5_WARNINGS_AND">Warnings and Precautions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_5_6_Pregnancy">5.6</a></span><span class="Italics">) and </span><span class="Italics"><a href="#_8_USE_IN">Use in Specific Populations</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_8_1_Pregnancy">8.1</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-16.3"></a><p></p>
<h2>
<span class="Bold">17.3</span><span class="Bold">
		     
	Nursing Mothers</span>
</h2>
<p class="First">
		     
	It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from gemcitabine for injection, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother <span class="Italics">[see </span><span class="Italics"><a href="#_8_USE_IN">Use in Specific Populations</a></span><span class="Italics"> (</span><span class="Italics"><a href="#_8_3_Nursing_Mothers">8.3</a></span><span class="Italics">)]</span>.</p>
<p><span class="Bold">Manufactured by:</span>  <br>Cipla Ltd.<br>Verna Goa, INDIA</p>
<p><span class="Bold">Manufactured for:</span> <br>Watson Laboratories, Inc.<br>Corona, CA 92880  USA</p>
<p><span class="Bold">Rx only</span><br>Issued:  April 2011<br>G523B<br><br></p>
<p><br><br><br><br><br><br><br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span><br><span class="Bold">200 mg/vial</span><span class="Bold"><br>NDC 0591-3562-79</span><br>Sterile Single Use Vial<br><span class="Bold">GEMCITABINE</span><br>for Injection, USP<br>200 mg<br>(lyophilized)<br><span class="Bold">DO NOT REFRIGERATE</span><br>(FOR I.V. USE ONLY)<br>Sterile Single Use Vial<br><span class="Bold">Watson</span><span class="Bold"><span class="Sub">®</span></span><span class="Bold"> Rx only</span></p>
<p><img alt="PRINCIPAL DISPLAY PANEL
200 mg/vial
NDC 0591-3562-79
Sterile Single Use Vial
GEMCITABINE
for Injection, USP
200 mg
(lyophilized)
DO NOT REFRIGERATE
(FOR I.V. USE ONLY)
Sterile Single Use Vial
Watson® Rx only
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd&amp;name=gemcitabine-for-injection-usp-06.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span><br><span class="Bold">1 </span><span class="Bold">g/vial</span><span class="Bold"><br>NDC 0591-</span><span class="Bold">3563-55</span><br>Sterile Single Use Vial<br><span class="Bold">GEMCITABINE</span><br>for Injection, USP<br>1 g<br>(lyophilized)<br><span class="Bold">DO NOT REFRIGERATE</span><br>(FOR I.V. USE ONLY)<br>Sterile Single Use Vial<br><span class="Bold">Watson</span><span class="Bold"><span class="Sub">®</span></span><span class="Bold"> Rx only</span></p>
<p><img alt="PRINCIPAL DISPLAY PANEL
1 g/vial
NDC 0591-3563-55
Sterile Single Use Vial
GEMCITABINE
for Injection, USP
1 g
(lyophilized)
DO NOT REFRIGERATE
(FOR I.V. USE ONLY)
Sterile Single Use Vial
Watson® Rx only
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd&amp;name=gemcitabine-for-injection-usp-07.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GEMCITABINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">gemcitabine hydrochloride injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-3562</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GEMCITABINE HYDROCHLORIDE</strong> (GEMCITABINE) </td>
<td class="formItem">GEMCITABINE</td>
<td class="formItem">200 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">200 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem">12.5 mg  in 5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0591-3562-79</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078759</td>
<td class="formItem">07/25/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GEMCITABINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">gemcitabine hydrochloride injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-3563</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GEMCITABINE HYDROCHLORIDE</strong> (GEMCITABINE) </td>
<td class="formItem">GEMCITABINE</td>
<td class="formItem">1 g  in 25 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">1 g  in 25 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem">62.5 mg  in 25 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0591-3563-55</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">25 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078759</td>
<td class="formItem">07/25/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Watson Laboratories, Inc.
							(966714656)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cipla Ltd.</td>
<td class="formItem"></td>
<td class="formItem">650072015</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cd20b1d6-481b-4840-b36b-9933555d8e4b</div>
<div>Set id: 6004fba9-49c0-4781-8134-44bf7cf196fd</div>
<div>Version: 6</div>
<div>Effective Time: 20110401</div>
</div>
</div> <div class="DistributorName">Watson Laboratories, Inc.</div></p>
</body></html>
